

RECOMBINANTLY MODIFIED PLASMIN

Cross-Reference to Related Applications

This application claims priority under 35 USC §119 to U.S. Provisional
5 Application 60/991,148, filed November 29, 2007, incorporated herein by reference.

Background of the Invention

Human plasminogen is a single-chain protein containing 791 amino acid
residues. Activation of plasminogen to plasmin results from a single cleavage of the
10 Arg561-Val562 peptide bond in the zymogen. The resulting plasmin molecule is a
two-chain, disulfide-linked serine protease with trypsin-like specificity (cleaves after
Lys and Arg).

The amino-terminal heavy chain of plasmin (residues 1-561, ~60 kDa) is
composed of five kringle domains, each containing approximately 80 amino acid
15 residues. The kringle domains are responsible for the regulatory properties of
plasminogen, such as interaction with activation inhibitors, *e.g.*, Cl^- ions; with
activation stimulators, *e.g.*, ϵ -aminocaproic acid; with mammalian and bacterial cells;
and with other proteins, such as plasmin physiological substrate fibrin and plasmin
inhibitor $\alpha 2$ -antiplasmin. Of all five kringles, kringle 1 is one of the most multi-
20 functional: its lysine-binding activity has been shown to be responsible for plasmin
interaction with $\alpha 2$ -antiplasmin and fibrin. See Wiman, B., *et al.*, *Biochim. Biophys.*
Acta 579:142-154 (1979); and Lucas, M.A., *et al.*, *J. Biol. Chem.* 258:4249-4256
(1983).

The C-terminal light chain of plasmin (residues 562-791, ~25kDa) is a typical
25 serine protease, homologous to trypsin and containing the classic serine protease
catalytic triad: His603, Asp646 and Ser741. Plasminogen contains 24 disulfide
bridges and 2 glycosylation sites on Asn289 and Thr346.

The limited proteolysis of plasminogen by elastase has been shown to result in
three major fragments (Sottrup-Jensen, L., *et al.*, *Prog. Chem. Fibrinol. Thrombol.*,
30 3:191-209 (1978)). First fragment, K1-3, includes the first three kringles and can be
isolated in two versions, Tyr80-Val338 and Tyr80-Val354. The second fragment, K4,
corresponds to the fourth kringle and includes residues Val355-Ala440. The last, C-
terminal fragment (the so-called mini-plasminogen) includes residues Val443-Asn791

and consists of the fifth kringle and the serine protease domain. Mini-plasminogen can be activated in the same way as plasminogen, forming mini-plasmin.

Because of the complex structure of the full-length plasminogen molecule, bacterial expression systems have not proven useful for recombinant plasminogen
5 production. Plasminogen is produced in the form of insoluble inclusion bodies and is not re-foldable from that state. Further, the expression of plasminogen in mammalian cells is complicated by intracellular activation of plasminogen into plasmin and the resulting cytotoxicity. Production of fully active plasminogen using insect cells is possible, however, this system is not suitable for large-scale production due to low
10 yield. Further, as with any recombinant protein scheme, the potential exists for encountering immunogenicity problems in the subject receiving the therapeutic recombinant protein.

Immunogenicity can be a barrier to the effective and/or efficient utilization of certain recombinant protein therapeutic schemes. Immunogenicity is a complex series
15 of responses to a substance (*e.g.*, the chemical structure of a protein including the amino acid sequence) that is perceived as foreign and may include production of neutralizing and non-neutralizing antibodies, formation of immune complexes, complement activation, mast cell activation, inflammation, and anaphylaxis. Immunogenicity may limit the efficacy and safety of a protein therapeutic in multiple
20 ways. Efficacy can be reduced directly by the formation of neutralizing antibodies. Efficacy may also be reduced indirectly, as binding to either neutralizing or non-neutralizing antibodies typically leads to rapid clearance from serum. Severe side effects and even death may occur when an immune reaction is raised. One special class of side effects results when neutralizing antibodies cross-react with an
25 endogenous protein and block its function.

Accordingly, a modified recombinant protein, possessing the desirable characteristics (*e.g.*, regions with native-like chemical structures) of plasmin/plasminogen while lacking certain negative characteristics and being capable of production in recombinant protein expression systems including bacterial cells in
30 substantial quantities, is desirable.

Summary of the Invention

In one aspect, the present invention provides a polynucleotide comprising a nucleotide sequence encoding a polypeptide having

a) a single N-terminal kringle domain homologous to a kringle domain of native human plasminogen, wherein the last four amino acid residues within the kringle domain are V,P,Q, and C; and

b) a C-terminal domain activation site and serine protease domain homologous to the corresponding domains in human plasminogen; wherein the polypeptide binds to immobilized lysine.

In another aspect, the present invention provides a polypeptide comprising:

a) a single N-terminal kringle domain homologous to a kringle domain of native human plasminogen, wherein the last four amino acid residues within the kringle domain are V,P,Q, and C; and

b) a C-terminal domain activation site and serine protease domain homologous to the corresponding domains in human plasminogen; wherein the polypeptide binds to immobilized lysine.

In other aspects, the present invention provides an expression vector comprising a polynucleotide of the present invention. In one embodiment, the polynucleotide comprises a nucleotide sequence as shown in SEQ ID NO:1.

In some aspects, the present invention provides a cultured cell comprising an expression vector comprising a polynucleotide of the present invention. In one embodiment, the polynucleotide comprises a nucleotide sequence as shown in SEQ ID NO:1. In another embodiment, the cultured cell is a prokaryotic organism. In one embodiment, the prokaryotic organism is *E. coli*.

In one aspect, the present invention provides a method for making one or more recombinant plasmin polypeptides. The method comprises:

a) providing a polypeptide having a single N-terminal kringle domain homologous to a kringle domain of native human plasminogen, wherein the last four amino acid residues within the kringle domain are V,P,Q, and C; and a C-terminal domain activation site and serine protease domain homologous to the corresponding domains in human plasminogen; wherein the polypeptide binds to immobilized lysine; and

b) contacting the polypeptide provided in step a) with a protease under conditions sufficient to cleave one or more peptide bonds thereby forming the one more recombinant plasmin polypeptides. In one embodiment, providing comprises expressing an open reading frame having a sequence corresponding to the sequence as shown in SEQ ID NO:1, or a degenerate variant thereof, in a suitable host. In another embodiment, the polypeptide has an amino acid sequence as shown in SEQ ID NO:2.

Brief Description of the Drawings

Figure 1 is a schematic representation of native plasmin after activation by proteolytic cleavage. K1-K5 are kringle regions 1-5; and SP is the serine protease domain. "α₂-AP" is the α₂-antiplasmin binding site on kringle 1.

Figure 2 is a schematic representation of a plasminogen deletion mutant of the invention using the same nomenclature as in Figure 1, and showing the deletion of K2-5.

Figure 3 shows the amino acid sequence of human plasminogen, showing the 19-residue leader sequence numbered as -19 to -1, and the plasminogen sequence shown as residues 1-791 (see SEQ ID NO:3, the cDNA sequence for human plasminogen; and SEQ ID NO:4, the encoded amino acid sequence, as shown in Figure 3). A number of features are shown, including the following: one embodiment of the (TAL6003)-plasminogen sequence (shaded); kringle domains 1-5 (double underscore); glycosylation sites Asn289 and Thr346 (in bold); the Arg-Val activation site (R⁵⁶¹V⁵⁶² in bold); and lysine-binding sites in kringle 1 (in underscore and with specific position numbering).

Figure 4 shows polypeptide sequence comparisons (*i.e.*, a gap alignment) between the five kringle domains (1-5) of native human plasmin(ogen). Amino acid residues that are identical to those of the same relative position in kringle 1 are shown in underscore.

Figure 5 shows a 8-25% gradient SDS-PAGE of plasma-derived plasmin (Lane 1= non-reduced (NR); Lane 2 = reduced (R)) and (TAL6003)-plasmin (Lane 3 = non-reduced (NR); Lane 4 = reduced (R)) preparation. Streptokinase activation of plasma-derived plasminogen and (TAL6003)-plasminogen into native plasmin and recombinant (TAL6003)-plasmin, respectively, results in the formation of two bands corresponding to the kringle and the serine protease domains. Accordingly, following

incubation with the reducing agent dithiotreitol (DTT) prior to electrophoresis, plasma-derived plasmin and (TAL6003)-plasmin, which are a single band on a non-reduced gel, reduce to two bands corresponding to kringle 1 (lower band) and the serine protease domain (upper band) in the same non-reduced gel.

5 Figure 6 is a graphic representation of activation of (TAL6003)-plasminogen by streptokinase.

Figure 7 is a chromatogram showing binding of (TAL6003)-plasminogen to lysine-SEPHAROSE 4B: 0.5 mg of purified (TAL6003)-plasminogen was applied on the lysine-SEPHAROSE 4B column (1x3 cm) equilibrated with Tris-buffered saline,
10 pH 7.4. Bound protein was eluted from the column by a 0-20 mM gradient of ϵ -aminocaproic acid (ϵ -ACA) as a single peak. The absorbance at 280 nm and the concentration of ϵ -ACA, as a function of the effluent volume are presented on the graph.

Figure 8 shows binding of (TAL6003)-plasminogen to fibrin as assessed by its
15 subsequent activation by tPA and resulting clot lysis.

Figure 9 shows *in vitro* comparison of the thrombolytic efficacy of (TAL6003)-plasmin with plasma-derived plasmin.

Figure 10 illustrates disulfide bonding pattern of (TAL6003)-plasmin (SEQ ID NO:2). In the figure, (X) represents the amino acid sequence RDVVLFEK.

20

Description of the Invention

The present inventors have discovered novel recombinant plasminogen polypeptides, or variants thereof, herein referred to as (TAL6003)-plasminogens that have native plasminogen-like features despite deletion of 4 kringles from its structure.
25 These (TAL6003)-plasminogens, or variants thereof, are zymogens that are capable of becoming activated to functional plasmin enzymes (herein referred to as (TAL6003)-plasmins) following an activation event that at least involves proteolytic cleavage of an Arg-Val peptide bond located between the kringle domain and the serine protease domain of the zymogen.

30 The (TAL6003)-plasminogen, or a variant thereof, of the present invention has fibrin- and antiplasmin-binding as well as activation properties of full-length native human plasminogen. Further, the (TAL6003)-plasminogen has a number of novel and desirable features including high level expression in recombinant production and

certain protein chemical structures identical or very similar to naturally occurring forms of human plasma-derived plasminogen.

The (TAL6003)-plasmin(ogen)s according to the present invention can be characterized at least by the following:

- 5 i) the lower molecular weights (*e.g.*, in one embodiment about 36,911 to about 37,039 Da) of (TAL6003)-plasmins created following activation of (TAL6003)-plasminogens result in increased specific activity (per mg of protein);
- ii) the lack of at least two glycosylation sites found in the native protein (see Figure 3, *i.e.*, N²⁸⁹ and T³⁴⁶), combined with the relatively low molecular weights,
10 facilitates recombinant production of this protein using relatively inexpensive bacterial and yeast expression systems;
- iii) (TAL6003)-plasminogens can be activated by plasminogen activators tPA, urokinase, and streptokinase;
- iv) the presence of the single N-terminal kringle domain homologous to a
15 kringle domain of native human plasminogen preserves the fibrin-binding properties of plasmin which are important for thrombolytic efficacy;
- v) the presence of α_2 -antiplasmin-binding sites on the single N-terminal kringle domain homologous to a kringle domain of native human plasminogen allows the (TAL6003)-plasmins to be inhibited rapidly by this physiological inhibitor of
20 plasmin (a feature which can prevent bleeding);
- vi) the smaller size of the (TAL6003)-plasmins can facilitate their inhibition by α_2 -macroglobulin, further lessening the chance of bleeding complications relative to native plasmin. In particular embodiments, the absence of kringle 5, which retains the primary binding site for intact, undigested fibrin(ogen), can allow use of the
25 (TAL6003)-plasmins with reduced depletion of circulating fibrinogen;
- vii) the presence of a single N-terminal kringle domain homologous to a kringle domain of native human plasminogen, wherein the last four amino acid residues within the kringle domain are V,P,Q, and C, provides a native-like linkage to the serine protease domain (*i.e.*, a linkage similar to the naturally occurring domain
30 juncture between the kringle 5 domain and the serine protease domain of human plasminogen); and

viii) following expression of the recombinant (TAL6003)-plasminogen, its N-terminus may be cleaved back (*e.g.*, cleaved back during activation) to provide a native-like N-terminus.

Generally, the invention provides recombinant (TAL6003)-plasmin(ogen)
5 polypeptides having a single kringle region N-terminal to the activation site and serine protease domain, having certain advantages relative to mini-plasmin(ogen). Although the (TAL6003)-plasminogens of the invention only have one kringle domain, as such, N-terminal to the activation site, some embodiments include additional sequences N-terminal to the activation site. Additional N-terminal sequences can be derived from
10 those of native kringle regions of plasminogen.

The N-terminal kringle domains of the present invention include kringle sequences of kringles 1 and 4 of native plasmin(ogen) and functional equivalents thereof. In particular, see the discussion below which provides guidance regarding preservation of function in polypeptide variants, including preservation of residues
15 participating in or influencing lysine-binding.

Further, particular embodiments of the polypeptides of the present invention can exhibit reduced immunogenicity by virtue of native-like structures. For example, in some embodiments, the recombinant plasminogen of the present invention has an N-terminus identical to that of one of the naturally occurring forms of human plasma-
20 derived plasminogen, which upon activation by streptokinase, produces plasmin polypeptides comprising native-like N-termini. Additionally, the novel polypeptides of the present invention have a sequence between the Kringle and Serine protease domains that is similar to the junction between Kringle 5 and the SP domain in naturally-occurring human plasmin.

25

Definitions

The terms “domain” and “region” of a polypeptide are generally synonymous as used herein, unless otherwise indicated to the contrary. When recited together with well-recognized structural or functional designations such as “kringle” or “serine
30 protease,” etc., such terms will introduce a polypeptide feature relating to at least some characteristic(s) commonly recognized and understood to be associated with the polypeptide structures corresponding to such designations.

A “cultured host cell,” as used herein, refers to a prokaryotic or eukaryotic cell that contains heterologous DNA that has been introduced into the cell by any means, *e.g.*, electroporation, calcium phosphate precipitation, microinjection, transformation, viral infection, and the like.

5 “Heterologous” as used herein means “of different natural origin” or representing a non-natural state. For example, if a cultured host cell is transformed with a DNA or gene derived from another organism, particularly from another species, that gene is heterologous with respect to that cultured host cell and also with respect to descendants of the cultured host cell which carry that gene. Similarly,
10 “heterologous” refers to a nucleotide sequence derived from and inserted into the same natural, original cell type, but which is present in a non-natural state, *e.g.*, a different copy number or under the control of different regulatory elements. Further, when used in the context of a nucleic acid or amino acid sequence, the term “heterologous” also may refer to any region of the sequence that is of a different
15 natural origin than another region of the same sequence. For example, if a recombinant protein comprises a kringle domain derived from apolipoprotein(a) and a serine-protease domain derived from plasminogen, the kringle domain and the serine protease domain are “heterologous” relative to each other, particularly if each domain is derived from a different species or organism.

20 A “vector” molecule is a nucleic acid molecule into which heterologous nucleic acid can be inserted which can then be introduced into an appropriate cultured host cell. Vectors preferably have one or more origins of replication, and one or more sites into which the recombinant DNA can be inserted. Vectors often have convenient means by which cells with vectors can be selected from those without, *e.g.*, they
25 encode drug resistance genes. Common vectors include plasmids, viral genomes, and (primarily in yeast and bacteria) “artificial chromosomes.”

 As used herein, the term “transcriptional control sequence” refers to nucleic acid sequences, such as initiator sequences, enhancer sequences and promoter sequences, which induce, repress, or otherwise control the transcription of protein
30 encoding nucleic acid sequences to which they are operably-linked.

 The term “polypeptide” is used interchangeably herein with the terms “peptide” and “protein.”

The terms “polynucleotide” and “nucleic acid” are used interchangeably herein, and can refer to any nucleic acid that contains the information necessary for the purpose indicated by the context. That is, the nucleic acid can be DNA or RNA, either single stranded or double stranded, or other nucleic acid, as long as the polymer is capable of representing the appropriate information, *e.g.*, in relation to an encoded peptide, and can include complementary sequences, *e.g.*, sense strands and anti-sense strands of nucleic acids polymers.

The term “variant” of a polypeptide refers to an amino acid sequence that is altered by one or more amino acids. The variant can have “conservative” changes, wherein a substituted amino acid has similar structural or chemical properties, *e.g.*, replacement of leucine with isoleucine. Alternatively, a variant can have “non-conservative” changes, *e.g.*, replacement of a glycine with a tryptophan. Analogous minor variation can also include amino acid deletion or insertion, or both. A particular form of a “variant” polypeptide is a “functionally equivalent” polypeptide, *i.e.*, a polypeptide which exhibits substantially similar *in vivo* or *in vitro* activity as the examples of the polypeptide of invention, as described in more detail below. Guidance in determining which amino acid residues can be substituted, inserted, or deleted without eliminating biological or immunological activity can be found using computer programs well-known in the art, for example, DNASTAR software (DNASTAR, Inc., Madison, WI). Further, specific guidance is provided below, including that provided within the cited references which are fully incorporated herein by reference.

The terms “N-terminal” and “C-terminal” are used herein to designate the relative position of any amino acid sequence or polypeptide domain or structure to which they are applied. The relative positioning will be apparent from the context. That is, an “N-terminal” feature will be located at least closer to the N-terminus of the polypeptide molecule than another feature discussed in the same context (the other feature possible referred to as “C-terminal” to the first feature). Similarly, the terms “5’-” and “3’-” can be used herein to designate relative positions of features of polynucleotides.

The polypeptides referred to herein as having an N-terminal domain “homologous to a kringle domain of native human plasminogen” exhibit structural and functional characteristics similar to native kringle domains of plasminogen.

Further, the polypeptides referred to herein as having an N-terminal domain
“homologous to kringle 1” exhibit characteristics similar to native kringle 1, at least to
the extent that the polypeptides can have a higher affinity for ω -aminocarboxylic
acids (and functional homologs such as *trans*-4-aminomethylcyclohexane-1-
5 carboxylic acid, a cyclic acid) than kringle 5. See, *e.g.*, Chang, Y., *et al.*,
Biochemistry 37:3258-3271 (1998), incorporated herein by reference, for conditions
and protocols for comparison of binding of isolated kringle domain polypeptides to 5-
aminopentanoic acid (5-APnA); 6-aminohexanoic acid (6-AHxA), also known as ϵ -
aminocaproic acid (ϵ ACA); 7-aminoheptanoic acid (7-AHpA); and *trans*-4-
10 aminomethylcyclohexane-1-carboxylic acid (t-AMCHA).

References to kringle domains “homologous to kringle 4” are defined
similarly, as noted above regarding the phrase “homologous to kringle 1.” That is,
they exhibit functional characteristics similar to kringle 4 of native human
plasminogen as discussed above. These polypeptides also bind immobilized lysine as
15 described above.

The polypeptides of the invention bind immobilized lysine. As used herein,
the phrase “binding immobilized lysine” means that the polypeptides so characterized
are retarded in their progress relative to mini-plasminogen when subjected to column
chromatography using lysine-SEPHAROSE as the chromatographic media.
20 Typically, the polypeptides of the invention can be eluted from such chromatographic
media (lysine affinity resins) using solutions containing the specific ligand, *e.g.*,
 ϵ ACA, as eluants.

Further, in addition to Chang *et al.*, *supra*, other references can be consulted
by those of skill in the art to determine which residues can be varied by conservative
25 or non-conservative substitution, deletion or addition to yield a deletion mutant within
the scope of the present invention. For example, the following references provide
information regarding particular residues of the native kringle domains that may be
important for binding of ω aminocarboxylic acids: U.S. Pat. No. 6,538,103 to Ji, *et*
al.; U.S. Pat. No. 6,218,517 to Suzuki; Douglas, J.T., *et al.*, *Biochemistry*
30 41(10):3302-10 (2002); Zajicek, J., *et al.*, *J. Mol. Biol.*, 301(2):333-47 (2000); Lee,
H., *et al.*, *Arch Biochem Biophys.*, 375(2):359-63 (2000); Castellino, F. and S.
McCance, *Ciba Found Symp.* 212:46-60 (1997); McCance, S., *et al.*, *J. Biol. Chem.*,
269:32405-32410 (1994); Rejante, M.R. and M. Llinas, *Eur. J. Biochem.*, 221(3):939-

49 (1994); Wu, T.P., *et al.*, *Blood Coagul. Fibrinolysis*, 5(2):157-66 (1994); Hoover, C.J., *et al.*, *Biochemistry*, 32(41):10936-43 (1993); Menhart, N., *et al.*, *Biochemistry*, 32:8799-8806 (1993); Thewes, T., *et al.*, *J. Biol. Chem.*, 265 (7):3906-3915 (1990); Novokhatny, V., *et al.*, *Thromb Res.*, 53(3):243-52 (1989); Motta, A., *et al.*,
5 *Biochemistry*, 26(13):3827-36 (1987); Novokhatny, V., *et al.*, *J. Mol. Biol.*, 179:215-232 (1984); Lerch, P.G., *et al.*, *Eur. J. Biochem.*, 107(1):7-13 (1980); Sottrup-Jensen, L., *et al.*, *Prog. Chem. Fibrinol. Thrombol.*, 3:191-209 (1978); and Wiman, B. and D. Collen, *Nature* 272, 549-545 (1978), all incorporated herein by reference in their entirety.

10 Because the present inventors have recognized that a valuable, simplified plasmin(ogen) molecule can be prepared having a single N-terminal kringle domain having advantageous functional characteristics (which can be evaluated, in part, by testing for the binding of immobilized lysine as described herein), the present invention can encompass other fibrin-binding domains or regions N-terminal to the
15 activation site. For example, the invention can include polypeptides in which the serine protease domain of plasmin is attached to a fibrin-binding kringle selected from a group including, but not limited to, kringle 4 of human plasminogen, kringle 2 of tPA, or a kringle of apolipoprotein (a). Further, the invention can include polypeptides in which a serine protease domain of plasmin is attached to any other
20 known fibrin-binding modules, such as the "finger" domain of tPA or fibronectin, or the FAB fragment of fibrin-specific IgG.

 In some aspects, the polypeptides of the present invention have protein chemical structures (*e.g.*, native-like N-terminus and native-like juncture between the kringle and the serine protease domain) that are identical to the chemical structures
25 found in the naturally occurring forms of human plasma-derived plasmin(ogen). Without being held to a particular theory, it is believed that certain features of a protein can contribute to its immunogenicity, including but not limited to its amino acid sequence. Accordingly, the present invention provides an effective protein therapeutic based on recombinant (TAL6003)-plasminogen by pre-emptively
30 reducing the potential immunogenicity of (TAL6003)-plasminogen through incorporation of amino acid sequences that resemble native human plasminogen sequences.

In one aspect, the recombinant (TAL6003)-plasminogen polypeptide of the present invention comprises a) a single N-terminal kringle domain homologous to a kringle domain of native human plasminogen, wherein the last four amino acid residues within the kringle domain are V,P,Q, and C; and b) a C-terminal domain activation site and serine protease domain homologous to the corresponding domains in human plasminogen; wherein the polypeptide binds to immobilized lysine. In one embodiment, the single N-terminal kringle domain is homologous to kringle 1 or kringle 4 of native human plasminogen. In some embodiments, the immobilized lysine is lysine bound to a solid support matrix selected from the group consisting of lysine-agarose, lysine-hydrogel, lysine-cross-linked agarose. In another embodiment, the immobilized lysine is lysine-cross-linked agarose.

The recombinant (TAL6003)-plasminogen polypeptides of the present invention can be activated by one of ordinary skill in the art to provide a (TAL6003)-plasmin polypeptide. In one embodiment, the (TAL6003)-plasmin polypeptide exhibits a fibrinolytic activity that is inhibited by α_2 -antiplasmin at a rate of inhibition that is at least about 5-fold faster than the rate of inhibition of the fibrinolytic activity of mini-plasmin by α_2 -antiplasmin. In another embodiment, the rate of inhibition is at least about 10-fold, 20-fold, 30-fold, or 40-fold faster than the rate of inhibition of mini-plasmin.

In one embodiment, the recombinant (TAL6003)-plasminogen polypeptide is at least 90% or 95%, or 98% identical to the sequence shown in SEQ ID NO: 2. In another embodiment, the single N-terminal kringle domain is at least 90% identical to the kringle 1 or kringle 4 domain of native human plasminogen; and the C-terminal domain is at least 90% identical to the activation site and serine protease domain of human plasminogen. In some embodiments, the polypeptide has an amino acid sequence as shown in SEQ ID NO: 2, and conservative substitutions thereof. In other embodiments, the polypeptide has an arginine residue at a relative position analogous to that of position 85 of the amino acid sequence shown in SEQ ID NO: 2.

In further embodiments, the single N-terminal kringle domain has at least one residue greater amino acid sequence identity with kringle 1 or kringle 4 of native human plasminogen than with kringle 5 of native human plasminogen, and wherein conservative substitutions of the single N-terminal kringle domain relative to the native sequences of kringles 1 and 4 of human plasminogen are not considered as

differing from the native sequences for purposes of the identity comparison with kringle 5.

For example, the (TAL6003)-plasminogen described in this invention makes use of amino acid residue modifications to the junction region joining the single
5 kringle domain and the serine protease domain. Accordingly, this juncture between the two domains more closely resembles the naturally occurring juncture between the kringle 5 domain and the serine protease domain of human plasminogen.

In another embodiment, the (TAL6003)-plasminogen described in this invention further comprises a native-like N-terminal sequence. The recombinantly
10 produced (TAL6003)-plasminogen can be cleaved off upon activation to provide recombinant (TAL6003)-plasmin polypeptides also having native-like N-termini.

In particular embodiments, residues at certain positions of the single N-terminal kringle domain of (TAL6003)-plasminogen are conserved relative to kringle 1 of native human plasminogen. These can be residues at positions associated with
15 disulfide bridging and lysine binding, and include Cys84, Cys105, Cys133, Cys145, Cys157, and Cys162, and Pro136-Pro140, Pro143-Tyr146, and Arg153-Tyr156, respectively (positions numbered as shown in Figure 3). Additionally, particular embodiments of the invention can be characterized chemically by contrast to mini-plasmin(ogen) which has an analogous domain composition (*i.e.*, kringle-serine
20 protease (K-SP) (see Sottrup-Jensen, L., *et al.*, Progress in Chemical Fibrinolysis and Thrombolysis, Vol. 3, (Eds: J. F. Davidson, *et al.*) Raven Press, New York (1978)) but, *inter alia*, lacks an arginine (Arg) at a relative position analogous to that of position 85 of the amino acid sequence shown in SEQ ID NO: 2. In some embodiments, the (TAL6003)-plasminogen of the invention comprises a single N-
25 terminal kringle domain comprising an Arg residue at a relative position analogous to that of position 85 of the amino acid sequence shown in SEQ ID NO: 2. Non-limiting examples of a relative position analogous to that of position 85 of the amino acid sequence shown in SEQ ID NO: 2 include Arg(153), Arg(234), Arg(324), and Arg(426) positions of the amino acid sequence shown in SEQ ID NO:4.

30 In other embodiments, the specific positions of the named residues can vary somewhat while still being present in the polypeptide at structurally and functionally analogous positions (*i.e.* relative to the kringle structure of the N-terminal domain; see Chang, Y., *et al.* as discussed above). In some embodiments, the single N-terminal

kringle domain of the (TAL6003)-plasmin(ogen) polypeptide has at least one residue greater percent identity with kringle 1 or kringle 4 of native human plasminogen than with kringle 5 of native human plasminogen.

Further, particular embodiments of the invention can be characterized functionally by contrast to mini-plasmin(ogen). In preferred embodiments, the (TAL6003)-plasmin of the invention exhibits an increased rate of inhibition by α_2 -antiplasmin, *e.g.*, as much as about one or two orders of magnitude faster than the rate of inhibition of mini-plasmin. Further, in particular embodiments, (TAL6003)-plasmin binds immobilized lysine (*e.g.*, lysine-SEPHAROSE).

Characterization of the single N-terminal kringle domain of (TAL6003)-plasminogen as "N-terminal" means only that the domain is present N-terminal to the activation site and does not mean that additional amino acids residues N-terminal to the domain itself are not present. Further, the number and identity of residues interposed between the most C-terminal cysteine residue of the single N-terminal kringle domain (*i.e.*, the most C-terminal Cys residue shown in Figure 4) and the activation site of plasminogen can be varied without departing from the scope of the present invention. One of skill in the art will be able to determine these variations that achieve the benefits of the invention (kringle 1-like binding of ω aminocarboxylic acids, without substantial increase in size of the deletion mutant or introduction of potentially problematic glycosylation sites) without undue experimentation based on the disclosure herein and the references cited herein for guidance regarding kringle 1 function and structure.

Accordingly, the invention relates to polynucleotides, polypeptides, recombinant methods for producing the polypeptides, vectors containing the polynucleotides, expression systems for producing the polypeptides, and cultured host cells comprising such expression systems.

As noted, in one aspect, the invention relates to a polynucleotide encoding the polypeptide disclosed herein or a polypeptide having conservative amino acid substitutions thereof. Guidance regarding selection of "conservative" amino acid substitutions is provided in more detail below. In one embodiment, the polynucleotide is DNA.

In another aspect, the invention relates to a method of making a vector comprising inserting the polynucleotide of the invention into a vector. In another aspect, the invention relates to a vector produced by the method of the invention.

5 In another aspect, the invention relates to a method of making a cultured host cell comprising introducing the vector of the invention into a cultured host cell. In another aspect, the invention relates to a cultured host cell produced by the method of the invention.

10 In another aspect, the invention relates to an isolated polypeptide of the invention, produced by a method comprising: (a) introducing a vector comprising a polynucleotide encoding the polypeptide into a cultured host cell; (b) culturing the host cell; and (c) recovering the polypeptide. In another aspect, the invention relates to a method for producing a polypeptide comprising: (a) culturing the host cell of the invention under conditions that the vector is expressed; and (b) recovering the polypeptide.

15 In another aspect, the invention relates to cells containing at least one polynucleotide of the invention.

In one embodiment, the polynucleotide comprises the nucleotide sequence as shown in SEQ ID NO:1. In another embodiment, the polynucleotide comprises nucleotides 4 through 1032 of the nucleotide sequence shown in SEQ ID NO:1. In other embodiments, the polypeptide comprises the amino acid sequence as shown in SEQ ID NO:2.

Polynucleotides

The polynucleotides of the invention include variants which have substitutions, deletions, and/or additions which can involve one or more nucleotides.

25 The variants can be altered in coding regions, non-coding regions, or both. Alterations in the coding regions can produce conservative or non-conservative amino acid substitutions, deletions or additions. Especially preferred among these are silent substitutions, additions and deletions, which do not alter the properties and activities of the (TAL6003)-plasmin(ogen) protein or portions thereof. Also especially preferred in this regard are conservative substitutions (see below).

30 Further embodiments of the invention include nucleic acid molecules comprising a polynucleotide having a nucleotide sequence at least 90% identical, and more preferably at least 95%, 96%, 97%, 98% or 99% identical to (a) a nucleotide

sequence encoding a polypeptide having the complete amino acid sequence in SEQ ID NO:2; (b) a nucleotide sequence encoding a polypeptide having the amino acid sequence in SEQ ID NO:2; and (c) a nucleotide sequence complementary to any of the nucleotide sequences in (a) or (b) above.

5 In one embodiment, the nucleic acid molecule of the present invention comprises a polynucleotide having a nucleotide sequence that encodes a polypeptide having the amino acid sequence shown in SEQ ID NO: 2. In other embodiments, the nucleic acid molecule comprises a polynucleotide having the nucleotide sequence shown in SEQ ID NO:1, or a degenerate variant thereof.

10 By a polynucleotide having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence encoding a (TAL6003)-plasminogen is intended that the nucleotide sequence of the polynucleotide be identical to the reference sequence except that the polynucleotide sequence can include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence
15 encoding the (TAL6003)-plasminogen polypeptide. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence can be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence can be inserted into the reference
20 sequence. These mutations of the reference sequence can occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence.

 As noted above, two or more polynucleotide sequences can be compared by
25 determining their percent identity. Two or more amino acid sequences likewise can be compared by determining their percent identity. The percent identity of two sequences, whether nucleic acid or peptide sequences, is generally described as the number of exact matches between two aligned sequences divided by the length of the shorter sequence and multiplied by 100. An approximate alignment for nucleic acid
30 sequences is provided by the local homology algorithm of Smith and Waterman, Advances in Applied Mathematics 2:482-489 (1981). This algorithm can be extended to use with peptide sequences using the scoring matrix developed by Dayhoff, Atlas of Protein Sequences and Structure, M. O. Dayhoff ed., 5 suppl. 3:353-358, National

Biomedical Research Foundation, Washington, D.C., USA, and normalized by Gribskov, *Nucl. Acids Res.* 14(6):6745-6763 (1986). An implementation of this algorithm for nucleic acid and peptide sequences is provided by the Genetics Computer Group (Madison, Wis.) in their BESTFIT utility application. The default
5 parameters for this method are described in the Wisconsin Sequence Analysis Package Program Manual, Version 8 (1995) (available from Genetics Computer Group, Madison, Wis.).

For example, due to the degeneracy of the genetic code, one of ordinary skill in the art will immediately recognize that a large number of the nucleic acid
10 molecules having a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to the nucleic acid sequence shown in SEQ ID NO:1 will encode a (TAL6003)-plasminogen polypeptide. In fact, because degenerate variants of these nucleotide sequences all encode the same polypeptide, this will be clear to the skilled artisan even without performing any functional assays or measurements described herein. It
15 will be further recognized in the art that, for such nucleic acid molecules that are not degenerate variants, a reasonable number will also encode a polypeptide having (TAL6003)-plasminogen polypeptide activity. This is because the skilled artisan is fully aware of amino acid substitutions that are either less likely or not likely to significantly effect protein function (*e.g.*, replacing one aliphatic amino acid with a
20 second aliphatic amino acid).

Recently, advances in the synthetic production of longer polynucleotide sequences have enabled the synthetic production of nucleic acids encoding significantly longer polypeptides without the use of traditional cloning techniques. Commercial providers of such services include Blue Heron, Inc., Bothell, WA
25 (<http://www.blueheronbio.com>). Technology utilized by Blue Heron, Inc. is described in U.S. Patent Nos. 6,664,112; 6,623,928; 6,613,508; 6,444,422; 6,312,893; 4,652,639; U.S. Published Patent Application Nos. 20020119456A1; 20020077471A1; and Published International Patent Applications (Publications Nos) WO03054232A3; WO0194366A1; WO9727331A2; and WO9905322A1, all
30 incorporated herein by reference.

Of course, traditional techniques of molecular biology, microbiology, and recombinant nucleic acid can also be used to produce the polynucleotides of the invention. These techniques are well known and are explained in, for example,

Current Protocols in Molecular Biology, F. M. Ausubel, ed., Vols. I, II and III (1997); Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989); DNA Cloning: A Practical Approach, D. N. Glover, ed., Vols. I and II (1985); Oligonucleotide
5 Synthesis, M. L. Gait, ed. (1984); Nucleic Acid Hybridization, Hames and Higgins, eds. (1985); Transcription and Translation, Hames and Higgins, eds. (1984); Animal Cell Culture, R. I. Freshney, ed. (1986); Immobilized Cells and Enzymes, IRL Press (1986); Perbal, "A Practical Guide to Molecular Cloning"; the series, Methods in Enzymology, Academic Press, Inc. (1984); Gene Transfer Vectors for Mammalian
10 Cells, J. H. Miller and M. P. Calos, eds., Cold Spring Harbor Laboratory (1987); and Methods in Enzymology, Wu and Grossman and Wu, eds., respectively, Vols. 154 and 155, all incorporated herein by reference.

Vectors and Cultured Host Cells

The present invention also relates to vectors which include the isolated nucleic
15 acid molecules of the present invention, cultured host cells which are genetically engineered with the recombinant vectors, and the production of the (TAL6003)-plasmin(ogen) polypeptides by recombinant techniques.

Recombinant constructs can be introduced into cultured host cells using well-known techniques such as infection, transduction, transfection, transvection,
20 electroporation and transformation. The vector can be, for example, a phage, plasmid, viral or retroviral vector. Retroviral vectors can be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing cultured host cells.

The polynucleotides can be joined to a vector containing a selectable marker
25 for propagation in a cultured host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it can be packaged *in vitro* using an appropriate packaging cell line and then transduced into cultured host cells.

Preferred are vectors comprising *cis*-acting control regions to the
30 polynucleotide of interest. Appropriate *trans*-acting factors can be supplied by the cultured host, supplied by a complementing vector or supplied by the vector itself upon introduction into the cultured host.

In certain embodiments in this regard, the vectors provide for specific expression, which can be inducible and/or cell type-specific. Particularly preferred among such vectors are those inducible by environmental factors that are easy to manipulate, such as temperature and nutrient additives.

5 Expression vectors useful in the present invention include chromosomal-, episomal- and virus-derived vectors, *e.g.*, vectors derived from bacterial plasmids, bacteriophage, yeast episomes, yeast chromosomal elements, viruses such as baculoviruses, papova viruses, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof,
10 such as cosmids and phagemids.

 DNA inserts should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the *E. coli* lac, trp and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further
15 contain sites for transcription initiation, termination and, in the transcribed region, a ribosome binding site for translation. The coding portion of the mature transcripts expressed by the constructs can include a translation initiating at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

20 As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase or neomycin resistance for eukaryotic cell culture and tetracycline or ampicillin resistance genes for culturing in *E. coli* and other bacteria. Representative examples of appropriate cultured hosts include, but are not limited to, bacterial cells, such as *E. coli*,
25 *Streptomyces* and *Salmonella typhimurium* cells; fungal cells, such as yeast cells; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described cultured host cells are known in the art.

 Among vectors preferred for use in bacteria include *e.g.*, pET24b or pET22b
30 available from Novagen, Madison, WI (pET-24b(+)) and pET-22b(+) = pET Expression System 24b (Cat. No. 69750) and 22b (Cat. No. 70765), respectively, EMD Biosciences, Inc., Novagen Brand, Madison, WI; see <http://www.emdbiosciences.com> product information section regarding pET-24b and

pET-22b for details regarding vector), pQE70, pQE60 and pQE-9, available from Qiagen Inc., Valencia, CA; pBS vectors, PHAGESCRIPT vectors, BLUESCRIPT vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene, LaJolla, CA; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia
5 (now Pfizer, Inc., New York, NY). Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan.

Bacterial promoters suitable for use in the present invention include the *E. coli*
10 lacI and lacZ promoters, the T3 and T7 promoters, the gpt promoter, the lambda PR and PL promoters, and the trp promoter. Suitable eukaryotic promoters include the CMV immediate early promoter, the HSV thymidine kinase promoter, the early and late SV40 promoters, the promoters of retroviral LTRs, such as those of the Rous sarcoma virus (RSV), and metallothionein promoters, such as the mouse
15 metallothionein-I promoter.

Introduction of a vector construct into the cultured host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection or other methods. Such methods are described in many standard laboratory manuals, such as Davis *et al.*,
20 Basic Methods In Molecular Biology, 2nd Edition (1995).

Transcription of the DNA encoding the polypeptides of the present invention by higher eukaryotes can be increased by inserting an enhancer sequence into the vector. Enhancers are *cis*-acting elements of DNA, usually about from 10 to 300 bp that act to increase transcriptional activity of a promoter in a given cultured host cell-
25 type. Examples of enhancers include the SV40 enhancer, which is located on the late side of the replication origin at bp 100 to 270, the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.

For secretion of the translated protein into the lumen of the endoplasmic
30 reticulum, into the periplasmic space or into the extracellular environment, appropriate secretion signals can be incorporated into the expressed polypeptide. The signals can be endogenous to the polypeptide or they can be heterologous signals.

The polypeptide can be expressed in a modified form, such as a fusion protein, and can include not only secretion signals, but also additional heterologous functional regions. For instance, a region of additional amino acids, particularly charged amino acids, can be added to the N-terminus, for example, the polypeptide to improve stability and persistence in the cultured host cell, during purification, or during subsequent handling and storage. Also, peptide moieties can be added to the polypeptide to facilitate purification. Such regions can be removed prior to final preparation of the polypeptide. The addition of peptide moieties to polypeptides to engender secretion or excretion, to improve stability and to facilitate purification, among others, are familiar and routine techniques in the art. A preferred fusion protein comprises a heterologous region from immunoglobulin that is useful to solubilize proteins. For example, EP 0 464 533 A1 (Canadian counterpart, 2,045,869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is thoroughly advantageous for use in therapy and diagnosis and thus results, for example, in improved pharmacokinetic properties. On the other hand, for some uses it would be desirable to be able to delete the Fc part after the fusion protein has been expressed, detected and purified in the advantageous manner described. This is the case when Fc portion proves to be a hindrance to use in therapy and diagnosis, for example when the fusion protein is to be used as antigen for immunizations. In drug discovery for example, human proteins have been fused with Fc portions for the purpose of high-throughput screening assays (such as hIL5-receptor, to identify antagonists of hIL-5). See, Bennett, D., *et al.*, *J. Molecular Recognition*, 8:52-58(1995) and Johanson, K. *et al.*, *J. Biol.Chem.*, 270(16):9459-9471 (1995).

(TAL6003)-plasminogen can be recovered and purified from recombinant cell cultures by well-known methods including those specifically described in the examples herein. Polypeptides of the present invention include naturally purified products, products of chemical synthetic procedures, and products produced by recombinant techniques from a prokaryotic or eukaryotic cultured host, including, for example, bacterial, yeast, higher plant, insect and mammalian cells. In addition, polypeptides of the invention can also include an initial modified methionine residue, in some cases as a result of host-mediated processes.

Polypeptides

The polynucleotides of the invention include those encoding variations and particular examples of the polypeptides of the invention. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in
5 Bowie, J. U. *et al.*, "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," *Science* 247:1306-1310 (1990), wherein the authors indicate that proteins are surprisingly tolerant of amino acid substitutions. Although any number of substitutions within the scope of the invention can be obtained by application of such general principles, for specific guidance regarding substitutions,
10 the references cited herein regarding structure and function of kringle 1 domains can be consulted by one of skill in the art.

It will further be appreciated that, depending on the criteria used, the exact "position" or sequence of the kringle, activation site, and serine protease domains of the (TAL6003)-plasminogen can differ slightly in particular variations within the
15 scope of the present invention. For example, the exact location of the kringle domain relative to the activation site can vary slightly and/or the sequence N-terminal to the kringle domain can vary in length. Thus, the invention includes such variations of the (TAL6003)-plasminogen polypeptides which exhibit (TAL6003)-plasminogen polypeptide activity as disclosed herein. Such variants include deletions, insertions,
20 inversions, repeats, and substitutions. As indicated above, guidance concerning which amino acid changes are likely to be phenotypically silent can be found in Bowie, J. U., *et al.*, "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," *Science* 247:1306-1310 (1990).

Thus, fragments, derivatives or analogs of the polypeptide of SEQ ID NO:2
25 can be (i) ones in which one or more of the amino acid residues (*e.g.*, 3, 5, 8, 10, 15 or 20 residues) are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue). Such substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) ones in which one or more of the amino acid residues includes a substituent group (*e.g.*, 3, 5, 8, 10, 15 or 20), or
30 (iii) ones in which the mature polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or (iv) ones in which the additional amino acids are fused to the mature polypeptide, such as an IgG Fc fusion region peptide or leader or secretory sequence

or a sequence which is employed for purification of the mature polypeptide or a proprotein sequence. Such fragments, derivatives and analogs are deemed to be within the scope of those skilled in the art from the teachings herein.

As indicated, changes are preferably of a minor nature, such as conservative amino acid substitutions that do not significantly affect the folding or activity of the protein. Of course, the number of amino acid substitutions a skilled artisan would make depends on many factors, including those described above. Generally speaking, the number of substitutions for any given (TAL6003)-plasminogen polypeptide will not be more than 50, 40, 30, 25, 20, 15, 10, 5 or 3.

Amino acids in the (TAL6003)-plasminogen of the present invention that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, *Science* 244:1081-1085 (1989)). The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity, *e.g.*, as shown in the examples provided herein. Sites that are critical for ligand binding can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith, *et al.*, *J. Mol. Biol.* 224:399-904 (1992) and de Vos, *et al.* *Science* 255:306-312 (1992)). Even if deletion of one or more amino acids from the N-terminus of a protein results in modification or loss of one or more biological functions of the protein, other biological activities can still be retained.

It is also contemplated that polypeptides useful in production of the "isolated polypeptides" of the invention can produced by solid phase synthetic methods. See Houghten, R. A., *Proc. Natl. Acad. Sci. USA* 82:5131-5135 (1985); and U.S. Pat. No. 4,631,211 to Houghten *et al.* (1986).

The polypeptides of the present invention can be provided in an isolated form. By "isolated polypeptide" is intended a polypeptide removed from its native environment. Thus, a polypeptide produced and/or contained within a recombinant cultured host cell is considered isolated for purposes of the present invention. Also intended as an "isolated polypeptide" are polypeptides that have been purified, partially or substantially, from a recombinant cultured host.

Polypeptides having an amino acid sequence of an indicated percent identity to a reference amino acid sequence of a (TAL6003)-plasminogen polypeptide can be

determined using the methods, including computer-assisted methods, indicated above regarding polynucleotides. Polypeptide amino acid sequences are examined and compared just as are the nucleotide sequences in the foregoing discussion. One of skill in the art will recognize that such concepts as the molecular endpoints discussed
5 for polynucleotides will have direct analogs when considering the corresponding use of such methods and programs for polypeptide analysis. For example, the manual corrections discussed regarding polynucleotides refer to 5' and 3' endpoints of nucleic acids, but the same discussion will be recognized as applicable to N-termini and C-termini of polypeptides.

10 The invention encompasses (TAL6003)-plasminogen polypeptides which are differentially modified during or after translation, *e.g.*, by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, *etc.* Any of numerous chemical modifications can be carried out by known techniques,
15 including but not limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, *S. aureus* V8 protease, NaBH₄; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; *etc.*

 Additional post-translational modifications encompassed by the invention include, for example, *e.g.*, N-linked or O-linked carbohydrate chains, processing of N-
20 terminal or C-terminal ends, attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and addition of an N-terminal methionine residue as a result of vectors and constructs adapted for expression of (TAL6003)-plasminogen polypeptides in prokaryotic cultured host cells. The polypeptides can also be modified with a detectable label,
25 such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the protein.

Pharmaceutical Compositions and Methods of Treatment

(TAL6003)-plasmin(ogen) can be formulated for therapeutic use in accordance with the methods and compositions described in U.S. Patent Application No. 10/143,112; and Novokhatny, V., *et al.*, *J. Thromb. Haemost.* 1(5):1034-41 (2003), both incorporated herein by reference. For example, a low-pH (from about 2.5 to about 4), low-buffering capacity buffer can be used for formulation of (TAL6003)-plasmin. Additionally, other methods and formulations known to those of skill in the art, as practiced with plasmin, mini-plasmin, and/or micro-plasmin, can be used to formulate the (TAL6003)-plasmin of the invention for therapeutic administration.

The (TAL6003)-plasmin(ogen) can be used to treat a variety of thrombotic diseases or conditions, for example, according to the methods as described in U.S. Patent Nos. 6,355,243, 6,964,764, and 6,969,515, all incorporated herein by reference. Again, as with the possible pharmaceutical formulations applicable to (TAL6003)-plasmin, (TAL6003)-plasmin can also be administered therapeutically by methods known in the art, for example, those that may be currently practiced with plasmin, mini-plasmin, and/or micro-plasmin.

EXAMPLES

Expression Vector Design

The amino acid sequence for (TAL6003)-plasminogen is shown in SEQ ID NO: 2. A polynucleotide having the nucleotide sequence encoding (TAL6003)-plasminogen was codon-optimized for *E. coli* expression and mRNA stability to provide the DNA sequence as shown in SEQ ID NO:1. This polynucleotide was cloned into the NdeI and BamHI sites of *E. coli* expression vector pET24b(+) (Novagen; Madison, WI) to produce cytosolic protein.

As illustrated in Table 1, expression in bacteria (*e.g.*, *E. coli*) provided a recombinant (TAL6003)-plasminogen polypeptide having the amino acid sequence as shown in SEQ ID NO:2 (*i.e.*, a recombinant (TAL6003)-plasminogen with an N-terminal methionine (*i.e.*, M¹) immediately preceding the arginine amino acid residue (*i.e.*, R²) corresponding to the arginine at position 70 (*i.e.*, R⁷⁰) of the native human plasminogen amino acid sequence shown in SEQ ID NO:4 (see also, *e.g.*, Fig. 3). Such a recombinant product was susceptible to further cleavage to yield additional

proteins having different N-termini including a protein with an N-terminal lysine (*i.e.*, K¹⁰) or valine (*i.e.*, V¹¹) corresponding, respectively, to the lysine at position 78 (*i.e.*, K⁷⁸) or the valine at position 79 (*i.e.*, V⁷⁹) of native human plasminogen.

5 Table 1: N-termini of native plasmin(ogen) (*e.g.*, based on SEQ ID NO:4) and (TAL6003)-plasmin(ogen) (*e.g.*, based on SEQ ID NO:2, or a variant thereof)

Native Plasminogen comprising 19 amino acid leader sequence (<i>e.g.</i> , based on SEQ ID NO:4):	
M ⁻¹⁹ EHKE ... E ⁰¹ PLDDY ... M ⁶⁹ R ⁷⁰ DVVLFEKK ⁷⁸ V ⁷⁹ YLSEC	↓ ↓
Native "Lys-Plasminogen" (<i>i.e.</i> , cleavage of leader sequence):	
E ⁰¹ PLDDY ... M ⁶⁹ R ⁷⁰ DVVLFEKK ⁷⁸ V ⁷⁹ YLSEC	↓ ↓
(SEQ ID NO:5)	
Native Plasmin species possible based on cleavage, if any, of Lys-Plasminogen:	
(SEQ ID NO:6) M ⁶⁹ R ⁷⁰ DVVLFEKK ⁷⁸ V ⁷⁹ YLSEC	
(SEQ ID NO:7) K ⁷⁸ V ⁷⁹ YLSEC	
(SEQ ID NO:8) V ⁷⁹ YLSEC	
Recombinant (TAL6003)-plasminogen polypeptides of the present invention:	
(e.g., based on SEQ ID NO:2) M ⁰¹ R ⁰² DVVLFEKK ¹⁰ V ¹¹ YLSEC	↓ ↓
Additional proteins based on further cleavage of a (TAL6003)-plasminogen:	
	(SEQ ID NO:9) K ¹⁰ V ¹¹ YLSEC
	(SEQ ID NO:10) V ¹¹ YLSEC

↓ indicates potential cleavage sites.

(TAL6003)-plasminogen Expression and Purification

The expression vector comprising the DNA encoding (TAL6003)-plasminogen was transformed into a variety of cells including BL21(DE3) RIL (Stratagene, La Jolla, CA), BL21(DE3) (genotype: *F^{ompT} hsdS_B (r_B⁻m_B⁻) gal dcm* (DE3)) (EMB Biosciences, Inc., San Diego, CA), and BLR(DE3) (genotype: *F^{ompT} hsdS_B (r_B⁻m_B⁻) gal dcm* (DE3) Δ (*srl-recA*)306::Tn10(Tet^R)), and protein over-expression following induction by 1mM IPTG (isopropyl-beta-D-thiogalactopyranoside) was analyzed by SDS-PAGE. Expression estimates were at least about 250 mg/L cell culture in shaker flasks.

Cell type BL21(DE3) RIL is engineered to express rare *E. coli* tRNAs coding for Arg, Ile, and Leu. Further, both BL21(DE3) and BLR(DE3) are B strain *E. coli* that is classified as non-pathogenic to humans and animals based on the absence of virulence and colonization factors. BLR(DE3) cells lack the *recA* gene for DNA recombination, and induction of lambda phage has not been reported with these cells.

A research cell bank of the (TAL6003)-plasminogen construct in BLR(DE3) cells was produced and tested for purity, identity, and induction of bacteriophage at Charles River Laboratories (Malvern, PA). The testing confirmed the identity and purity of the research cell bank and the cells passed the phage induction test with no phage
5 observed (data not shown).

Production of (TAL6003)-plasminogen (*i.e.*, based on SEQ ID NO:2) was confirmed in larger scale expression in which cells were lysed and both soluble protein and purified inclusion bodies were examined by SDS-PAGE.

The following typical protocol has been used for expression of (TAL6003)-
10 plasminogen:

A single colony of *E. coli* cells (*e.g.*, BL21(DE3) RIL, BL21(DE3), or BLR(DE3) containing the (TAL6003)-plasminogen vector was used to inoculate 5 ml of LB/kanamycin (30 µg/ml) and was incubated for 8 hours at 37°C on a shaker. After that, a 50 µl-aliquot was taken from the cultured bacterial suspension for further
15 growth in fresh media. The procedure was repeated after 16 hours with 6 ml of bacterial culture and 250 ml of the media. Cultures were grown at 37°C with shaking to an OD_{600 nm} of ~ 1.0, and IPTG was added to 1 mM final concentration. Cultures were grown for an additional 5 hours. Cells were harvested by centrifugation at 5,000 x g and cell pellets were dissolved in 20 mM Tris pH 8.0 containing 20 mM EDTA
20 and frozen at -80 °C.

To purify (TAL6003)-plasminogen, cell pellets were thawed and buffer added until the solution volume was approximately 1/20th that of the original cell culture volume. After that, lysozyme was added to a final concentration of 0.5 mg/ml and the cells were stirred rapidly at 4°C for 10 - 15 minute. Then, Triton X-100 was added to
25 1% final concentration and stirring continued for another 10 min. DNase I (0.05 mg/ml) and MgCl₂ (2.5 mM) were added and stirring was continued at 4°C for 30 minutes or until the solution was no longer viscous. The final solution was centrifuged at 4°C for 30 min at 15,000 x g and the supernatant was discarded.

The cell pellet was washed three times with wash solution (50 mM Tris-HCl, pH 7.4 containing 10 mM EDTA, 1% Triton-X-100, and 0.5 M urea), and the final
30 pellet was dissolved in 40 ml of extraction buffer (PBS, pH 7.4 containing 10 mM EDTA, 20 mM DTT, and 6 M guanidine-HCl) and stored at 4 °C overnight. After 16 hours, the solution was centrifuged for 30 minutes at 15,000 x g to remove solids and

the supernatant was slowly added to the refolding solution (50 mM Tris-HCl, pH 8.3, 3.5 M guanidine HCl, 0.5 M arginine HCl, 10 mM EDTA, 3 mM GSH, 0.3 mM GSSG) while stirring at 4°C. The refolding procedure was carried out at protein concentration of about 0.29 g/L.

5 The refolding solution was kept for 2 days at 4°C undisturbed and then dialyzed against an 8-fold volume of 0.1 M Tris-HCl pH 8.0 containing 10 mM EDTA, 0.15 M NaCl, 0.15 M arginine-HCl, over a period of 8-10 hours with frequent changes of the buffer solution.

 The protein solution was then removed from dialysis and concentrated using
10 AMICON filters with the membrane cut-off of 10 kDa to approximately 10–20 ml and dialyzed overnight versus a 100-fold volume of 0.1 M Tris pH 8.0 containing 10 mM EDTA, 0.15 M NaCl. This material was centrifuged to remove particulates, then passed over lysine affinity resin (Lysine-SEPHAROSE 4B; Amersham Biosciences, Piscataway, NJ). (TAL6003)-plasminogen was eluted from the resin using Tris-
15 buffered saline, pH 8.0 containing 0.2 M epsilon aminocaproic acid (εACA).

 Typically, 80 mg of inclusion bodies could be isolated from 1 liter of cell culture and 40 mg could be eluted in the lysine-SEPHAROSE chromatography step.

Properties of (TAL6003)-plasminogen

 Purified (TAL6003)-plasminogen appeared as a band in the 35-40 kDa region
20 by SDS-PAGE analysis of reduced (dithiothreitol-treated) and non-reduced protein. Its molecular mass, determined by MALDI mass-spectrometry, was about 38,140 Da, which is close to the expected value.

 To determine the rate of activation of (TAL6003)-plasminogen by streptokinase, 1 mg/ml of recombinant (TAL6003)-plasminogen was mixed with
25 streptokinase at a 1:100 (TAL6003)-plasminogen to streptokinase ratio and incubated at room temperature at pH 7. At various time points, samples were removed and quenched with SDS-Page buffer and analyzed on reduced SDS-PAGE followed by densitometry to determine the conversion of the one-chain (TAL6003)-plasminogen molecule into a two-chain (TAL6003)-plasmin. Percent activation of (TAL6003)-
30 plasminogen by streptokinase is shown in Figure 6 as loss of full-length (TAL6003)-plasminogen over time as determined by SDS-PAGE.

 To confirm the functionality of kringle 1, we determined the binding of TAL6003-plasminogen to lysine-SEPHAROSE 4B. As shown in Figure 7,

(TAL6003)-plasminogen bound to lysine-SEPHAROSE and could be eluted from the column by a 0-20 mM ϵ ACA gradient as a single peak at about 4 mM. The ability of refolded (TAL6003)-plasminogen to bind lysine-SEPHAROSE indicates that the kringle domain of the molecule is properly folded and the lysine-binding site is fully
5 active.

To further confirm the functionality of kringle 1, the binding of ϵ ACA to (TAL6003)-plasminogen was measured by monitoring the associated changes in protein fluorescence as described by Matsuka *et al.*, Eur. J. Biochem., 190:93-97 (1990) and Douglas *et al.*, J. Biochemistry 41:3302-3310 (2002), all incorporated
10 herein by reference. Binding of ϵ ACA to kringle 1 of (TAL6003)-plasminogen results in a decrease in fluorescence, likely due to quenching of the tryptophan residues which are part of the lysine-binding site.

To monitor this process, 4 μ l to 16 μ l aliquots of a concentrated solution of ϵ ACA were added to 2 ml of 5 μ M (TAL6003)-plasminogen in 50 mM Tris buffer
15 containing 20 mM NaCl, pH 8.0, 25°C. The fluorescence was monitored at an excitation wavelength of 298nm and an emission wavelength of 340nm in a FLUOROMAX fluorescence spectrophotometer (Jobin Yvon, Inc., Edison, NJ); after each addition of ϵ ACA, the solution was allowed to equilibrate until no further changes in fluorescence were observed.

20 The resulting fluorescence values were corrected for dilution and plotted versus the concentration of ϵ ACA over a range of 0 - 50 μ M ϵ ACA. Data were fitted by non-linear regression to obtain a K_d of about 19 μ M.

One property of plasminogen is its ability to bind fibrin. In order to determine whether (TAL6003)-plasminogen retains the ability to interact with fibrin, its fibrin-
25 binding properties was tested in a microtiter plate assay in which binding of (TAL6003)-plasminogen to fibrin was assessed by its subsequent activation by tPA and resulting clot lysis. For this purpose, 100 μ l of 5mg/ml fibrinogen was polymerized with thrombin in each well of a microtiter plate. Various concentrations of (TAL6003)-plasminogen was added on top of the fibrin clots and incubated for 1
30 hour at 37°C. The plate was washed extensively with PBS while the fibrin clots are still intact and attached to the wells. After washing, a 0.1 mg/ml solution of tPA was added to each well and the plate was incubated 2 hours at 37°C. As a result, some of the clots were completely dissolved and some were partially dissolved, while wells

with very low amounts of (TAL6003)-plasminogen and control wells remained practically intact. The degree of fibrinolysis was monitored by measuring the 280nm absorbance of remainders of the initial clots reconstituted in 1M NaOH. The absorbance values were plotted as a function of (TAL6003)-plasminogen concentration.

As shown in Figure 8, the binding of (TAL6003)-plasminogen to fibrin followed a classic, sigmoidal binding curve. Using this assay, it was found that (TAL6003)-plasminogen binds fibrin with affinity comparable to that of full-length plasminogen and the C_{50} of this interaction ($\sim 0.3 \mu\text{M}$) is comparable to the K_d of fibrin-binding of full-length plasminogen.

These experiments indicate that (TAL6003)-plasminogen can bind fibrin. Further, at least the interaction of (TAL6003)-plasminogen with lysine-Sepharose, its ability to bind ϵ ACA with the expected K_d , its ability to bind fibrin, and its ability to be activated by a plasminogen activator all indicated that this molecule was produced in the *E. coli* system in a fully functional form.

(TAL6003)-plasmin Purification and Formulation

The addition of SK to the purified (TAL6003)-plasminogen solution effects the conversion of (TAL6003)-plasminogen to (TAL6003)-plasmin. The protein was concentrated to 2 mg/ml and diluted 1:1 with 50% glycerol to produce a 1mg/ml solution in 25% glycerol. The solution was brought to room temperature and streptokinase was added at a 1:100 molar ratio of SK: (TAL6003)-plasminogen. The reaction was incubated without stirring at room temp for 4.5 hrs. The reaction was then slowed down by addition of NaCl to a 0.5 M final concentration. Analysis of activation by SDS-PAGE indicated a 90% yield of activated protein.

Activated (TAL6003)-plasmin was purified by Benzamidine Affinity Chromatography. The purpose of benzamidine affinity purification was the separation of unactivated (TAL6003)-plasminogen and impurities, including (TAL6003)-plasmin degradation products, from active (TAL6003)-plasmin. The SK activation solution was applied to an equilibrated Benzamidine-SEPHAROSE 4 Fast Flow column. The (TAL6003)-plasmin, both clipped and intact, was captured by the affinity resin while the aforementioned impurities flowed through the column. The column was washed with the equilibration buffer until the absorbance at 280 nm

reached baseline. The bound (TAL6003)-plasmin was then eluted using a low pH ϵ ACA step to strip all remaining protein from the column. Typical yields were 75%, with protein that is 95% active as measured by chromogenic plasmin potency assay.

Because (TAL6003)-plasmin, similar to full-length plasmin, is prone to auto-degradation at physiological pH, pH 3.6 was chosen for the final formulation (acidified with acetic acid-saline). As shown previously for plasmin by Novokhatny *et al.*, J Thromb Haemost., 1(5):1034-41 (2003), incorporated by reference, and confirmed in experiments with (TAL6003)-plasmin, this low buffering-capacity, low pH formulation not only allows safe storage of active plasmins for prolonged periods of time, but is also compatible with parenteral administration of these direct thrombolytics. When mixed with plasma or neutral pH buffers, (TAL6003)-plasmin is quickly re-activated.

Enzymatic Properties of (TAL6003)-plasmin

The amidolytic activity of (TAL6003)-plasmin was examined using the plasmin substrate D-Val-Leu-Lys-p-nitroanilide (S-2251) (DiaPharma, West Chester, OH).

For (TAL6003)-plasmin, at pH 7.4, 25°C in PBS buffer, the Michaelis-Menten constant (K_M) for S-2251 was found to also be 141 μ M (Table 3). The k_{cat} for the preparation was found to be about 725 min^{-1} . Using 4-nitrophenyl 4-guanidinobenzoate hydrochloride (pNPGb) titration (Chase, T. and E. Shaw, *Methods Enzymol.* 197:20-27(1970)), the percent of functional active sites was found to be 67%. Correcting k_{cat} for percent active sites, a k_{cat} of about 725 min^{-1} was determined. This value was very close to the value determined in the same assay for full-length plasmin, 820 $\pm$ 23 min^{-1} and for micro-plasmin (lacking all five kringles), 795 $\pm$ 24 min^{-1} . These data indicate that presence or absence of kringles does not affect the catalytic activity of the serine protease domain.

Table 3. Steady-state kinetic parameters for various plasmin species with substrate S-2251, in PBS buffer, pH 7.4, 25 °C.

	K_M	K_{CAT}
plasmin	220 $\pm$ 9 μ M	820 $\pm$ 23 min^{-1}
mini-plasmin	160 $\pm$ 30 μ M	770 $\pm$ 70 min^{-1}
micro-plasmin	145 $\pm$ 13 μ M	795 $\pm$ 24 min^{-1}
(TAL6003)-plasmin	141 $\pm$ 9 μ M	725 min^{-1}

The rate of inhibition of (TAL6003)-plasmin by α_2 -antiplasmin was determined to be $1.8 \pm 0.06 \times 10^7 \text{ M}^{-1}\text{s}^{-1}$ using the method of Wiman and Collen (Wiman, B. and D. Collen, *Eur. J. Biochem.* 84:573-578 (1978)) in which plasmin and α_2 -antiplasmin are mixed then assayed for S-2251 activity at specific time points (Table 4). This value is comparable to reported values for plasmin of $2.5 \times 10^7 \text{ M}^{-1}\text{s}^{-1}$ (from Anonick, *et al.*, *Thrombosis Res.* 59:449 (1990)).

Table 4. Inhibition rates for various plasmin species and inhibitors were determined at 22°C in PBS buffer, pH 7.4.

	α_2 -antiplasmin
plasmin	$2.5 \pm 0.5 \times 10^7 \text{ M}^{-1}\text{s}^{-1}$ (lit.)
mini-plasmin	$2.4 \pm 0.5 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$
micro-plasmin	$1.8 \pm 0.2 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$
(TAL6003)-plasmin	$1.8 \pm 0.06 \times 10^7 \text{ M}^{-1}\text{s}^{-1}$

The same experiments conducted with micro-plasmin revealed α_2 -antiplasmin inhibition rates of $1.8 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$ and $3.1 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$ in two separate experiments. The rate of α_2 -antiplasmin inhibition of mini-plasmin (mini-plasmin domain composition, K5-SP) was determined to be $2.4 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$. These data are in reasonable agreement with literature values for micro- and mini-plasmin and show that inhibition of (TAL6003)-plasmin by α_2 -antiplasmin is 40-fold faster than the inhibition of either micro-plasmin or mini-plasmin. Thus, these results indicate that (TAL6003)-plasmin should be rapidly inhibited by α_2 -antiplasmin due to the presence of kringle 1 in its structure. Overall, the data presented in this section show that the enzymatic and inhibitory properties of (TAL6003)-plasmin is similar to full-length plasmin.

Literature values are taken from Anonick, *et al.*, *Thrombosis Res.* 59:449(1990). All rates were measured according to the methods published in Anonick, *et al.*

***In Vitro* Fibrinolytic Efficacy**

The fibrinolytic efficacy of (TAL6003)-plasmin was tested in an *in vitro* model of clot lysis assay using the following experimental protocol.

In vitro comparison of the thrombolytic efficacy of (TAL6003)-plasmin with plasma-derived plasmin. Equimolar amounts of plasma-derived plasmin (0.25 mg/ml) and (TAL6003)-plasmin (0.11 mg/ml) were mixed with blood clots in the test

tube and degree of clot lysis was monitored by A_{280} absorbance of material released from the clot.

The concentrations of plasmin or (TAL6003)-plasmin required to overcome plasma inhibitors in the presence of fibrin and initiate clot lysis are shown in Figure 9.

CLAIMS

1. A polynucleotide comprising a nucleotide sequence encoding a polypeptide that is at least 95% identical to SEQ ID No. 2, having
 - a) a single N-terminal kringle domain homologous to a kringle domain of native human plasminogen, wherein the last four amino acid residues within the kringle domain are V, P, Q, and C; and
 - b) a C-terminal domain activation site and serine protease domain homologous to the corresponding domains in human plasminogen; wherein the polypeptide binds to immobilized lysine.
2. The polynucleotide of claim 1, wherein the encoded polypeptide is the sequence shown in SEQ ID NO: 2.
3. The polynucleotide of claim 1, wherein the nucleotide sequence of the polynucleotide is the sequence shown in SEQ ID NO: 1, or a degenerate variant thereof.
4. The polynucleotide of claim 1, wherein the polypeptide exhibits a lower binding affinity for fibrinogen than the binding affinity for fibrinogen of mini-plasmin.
5. The polynucleotide of claim 1, wherein the polypeptide exhibits higher binding affinity for partially cleaved fibrin than the binding affinity for partially cleaved fibrin of mini-plasmin.
6. The polynucleotide of claim 1, wherein the polypeptide has reduced immunogenicity as compared to a reference polypeptide, wherein the reference polypeptide has a primary amino acid sequence identical to the primary amino acid sequence of the polypeptide with the proviso that the last four amino acid residues of the single N-terminal kringle domain of the reference polypeptide is not V, P, Q, and C.
7. A polypeptide encoded by the polynucleotide according to any one of claims 1 to 6.
8. The polypeptide of claim 7, wherein the polypeptide exhibits a fibrinolytic activity that is inhibited by α 2-antiplasmin at a rate of inhibition that is at least about 5-fold faster than the rate of inhibition of the fibrinolytic activity of mini-plasmin by α 2-antiplasmin.

9. The polypeptide of claim 7, wherein the polypeptide has an amino acid sequence as shown in SEQ ID NO: 2, and conservative substitutions thereof.
10. The polypeptide of claim 7, wherein the polypeptide has an arginine residue at a relative position analogous to that of position 85 of the amino acid sequence shown in SEQ ID NO: 2.
11. An expression vector comprising the polynucleotide of claim 1.
12. A cultured cell comprising the expression vector of claim 11.
13. A method for making one or more recombinant plasmin polypeptides having different N-termini, the method comprising:
 - a) providing a polypeptide according to claim 7; and
 - b) contacting the polypeptide provided in step a) with a protease under conditions sufficient to cleave one or more peptide bonds thereby forming one or more recombinant plasmin polypeptides having different N-termini.
14. The method of claim 13, wherein the polypeptide has an amino acid sequence shown in SEQ ID NO: 2.
15. The method of claim 13, wherein providing comprises expressing a DNA sequence shown in SEQ ID NO: 1, or a degenerate variant thereof, in *E. Coli*.

SEQUENCE LISTING

<110> Talecris Biotherapeutics, Inc.
Novokhatny, Valery

<120> Recombinantly Modified Plasmin

<130> T126 1190.PCT

<150> US 60/991,148

<151> 2007-11-29

<160> 15

<170> PatentIn version 3.5

<210> 1

<211> 1032

<212> DNA

<213> Artificial sequence

<220>

<223> Nucleotide sequence encoding a polypeptide having a single N-terminal kringle domain homologous to a kringle domain of a native human plasminogen

<400> 1

atgctgtgatg tcgtcttatt cgagaagaaa gtctatttat ctgaatgtaa aacaggcaat	60
ggtaaaaact atcgcggtac catgtccaaa acaaaaaacg gtatcacttg tcaaaaatgg	120
tctagcactt caccatcatg tcctcgtttc tcccctgcga cccatccctc tgaaggcctc	180
gaagaaaact actgccgcaa ccccgataat gatcctcaag gcccattggtg ttatactacc	240
gacctgaaa aacgttatga ctattgcatg gtcccacaat gcgcagcccc ttcttttgat	300
tgcggcaaac cacaagttga acccaagaaa tgtccagggtc gtgttgctcg cggttggtt	360
gcgcaccccc acagttggcc gtggcagggtc tcattacgta cccggtttgg aatgcacttt	420
tgtggcggca ctctcatctc gcccgaaatgg gttcttacag ctgcacactg tttggaaaaa	480
agcccccgtc cttcttctta taaagttatc ctcggcgcac atcaagaagt caatttagaa	540
cctcatgtac aagaaatcga agtatctcgt ttattcctgg aaccgactcg caaagacatc	600
gcattactta aactgtcctc ccccgctgtg atcaccgata aagtaattcc cgcgtgttta	660
ccttctccta attatgttgt tgcagatcgt acagaatgct ttattaccgg ctgggggtgaa	720
actcaaggta cttttggtgc gggactcctg aaagaagcac agttaccagt catcgaaaac	780
aaagtatgta atcgctacga attcttaaac ggctcgtgttc aatccacaga attgtgcgca	840
ggtcatttag cagggtggcac tgatagctgt caagggtgatt cagggtgtcc tctcgtatgt	900
ttcgaaaaag ataaatatat tctgcaaggc gtcacctctt ggggtttagg ttgtgctcgt	960
ccaataaac ctggtgtata tgtacgtgta agtcgttttg ttacctggat tgaagggtgtt	1020
atgcggaaca ac	1032

<210> 2

<211> 344

<212> PRT

<213> Artificial sequence

<220>

<223> Polypeptide having a single N-terminal kringle domain homologous to a kringle domain of a native human plasminogen

<400> 2

Met Arg Asp Val Val Leu Phe Glu Lys Lys Val Tyr Leu Ser Glu Cys

T126

1	5	10	15
Lys Thr Gly	Asn Gly Lys Asn Tyr	Arg Gly Thr Met Ser	Lys Thr Lys
	20	25	30
Asn Gly Ile	Thr Cys Gln Lys Trp	Ser Ser Thr Ser	Pro His Arg Pro
	35	40	45
Arg Phe Ser	Pro Ala Thr His	Pro Ser Glu Gly	Leu Glu Glu Asn Tyr
	50	55	60
Cys Arg Asn	Pro Asp Asn Asp Pro Gln Gly	Pro Trp Cys Tyr Thr	Thr
	65	70	75
Asp Pro Glu	Lys Arg Tyr Asp Tyr Cys	Asp Val Pro Gln Cys	Ala Ala
	85	90	95
Pro Ser Phe	Asp Cys Gly Lys Pro Gln	Val Glu Pro Lys	Lys Cys Pro
	100	105	110
Gly Arg Val	Val Gly Gly Cys Val	Ala His Pro His Ser	Trp Pro Trp
	115	120	125
Gln Val Ser	Leu Arg Thr Arg	Phe Gly Met His	Phe Cys Gly Gly Thr
	130	135	140
Leu Ile Ser	Pro Glu Trp Val	Leu Thr Ala Ala	His Cys Leu Glu Lys
	145	150	155
Ser Pro Arg	Pro Ser Ser Tyr Lys	Val Ile Leu Gly	Ala His Gln Glu
	165	170	175
Val Asn Leu	Glu Pro His Val	Gln Glu Ile Glu	Val Ser Arg Leu Phe
	180	185	190
Leu Glu Pro	Thr Arg Lys Asp	Ile Ala Leu Leu Lys	Leu Ser Ser Pro
	195	200	205
Ala Val Ile	Thr Asp Lys Val	Ile Pro Ala Cys	Leu Pro Ser Pro Asn
	210	215	220
Tyr Val Val	Ala Asp Arg Thr	Glu Cys Phe Ile	Thr Gly Trp Gly Glu
	225	230	235
Thr Gln Gly	Thr Phe Gly Ala Gly	Leu Leu Lys Glu	Ala Gln Leu Pro
	245	250	255
Val Ile Glu	Asn Lys Val Cys	Asn Arg Tyr Glu	Phe Leu Asn Gly Arg
	260	265	270
Val Gln Ser	Thr Glu Leu Cys	Ala Gly His Leu	Ala Gly Gly Thr Asp
	275	280	285
Ser Cys Gln	Gly Asp Ser Gly	Gly Pro Leu Val	Cys Phe Glu Lys Asp
	290	295	300
Lys Tyr Ile	Leu Gln Gly Val	Thr Ser Trp Gly	Leu Gly Cys Ala Arg

305 310 315 T126 320

Pro Asn Lys Pro Gly Val Tyr Val Arg Val Ser Arg Phe Val Thr Trp
325 330 335

Ile Glu Gly Val Met Arg Asn Asn
340

<210> 3
<211> 2430
<212> DNA
<213> Homo sapiens

<400> 3
atggaacata aggaagtggg tcttctactt cttttatttc tgaaatcagg tcaaggagag 60
cctctggatg actatgtgaa tacccagggg gcttctactgt tcagtgtcac taagaagcag 120
ctgggagcag gaagtataga agaatgtgca gcaaaatgtg aggaggacga agaattcacc 180
tgcagggcat tccaatatca cagtaaagag caacaatgtg tgataatggc tgaaaacagg 240
aagtcctcca taatcattag gatgagagat gtagttttat ttgaaaagaa agtgtatctc 300
tcagagtgca agactgggaa tggaaagaac tacagaggga cgatgtccaa aacaaaaaat 360
ggcatcacct gtcaaaaatg gagttccact tctccccaca gacctagatt ctcacctgct 420
acacaccct cagagggact ggaggagaac tactgcagga atccagacaa cgatccgcag 480
gggccctggg gctatactac tgatccagaa aagagatatg actactgcga cattcttgag 540
tgtgaagagg aatgtatgca ttgcagtgga gaaaactatg acggcaaaat ttccaagacc 600
atgtctggac tggaatgcca ggccctgggac tctcagagcc cacacgctca tggatacatt 660
ccttccaaat ttccaaacaa gaacctgaag aagaattact gtcgtaacct cgatagggag 720
ctgcggcctt ggtgtttcac caccgacccc aacaagcgct gggaactttg cgacatcccc 780
cgctgcacaa cacctccacc atcttctggg cccacctacc agtgtctgaa gggaacaggt 840
gaaaactatc gcgggaatgt ggctgttacc gtttccgggc acacctgtca gcaactggagt 900
gcacagaccc ctcacacaca taacaggaca ccagaaaact tcccctgcaa aaatttggat 960
gaaaactact gccgcaatcc tgacggaaaa agggcccat ggtgccatac aaccaacagc 1020
caagtgcggg gggagtactg taagataccg tcctgtgact cctccccagt atccacggaa 1080
caattggctc ccacagcacc acctgagcta acccctgtgg tccaggactg ctaccatggg 1140
gatggacaga gctaccgagg cacatcctcc accaccacca caggaaagaa gtgtcagtct 1200
tggtcatcta tgacaccaca ccggcaccag aagaccccag aaaactacct aaatgctggc 1260
ctgacaatga actactgcag gaatccagat gccgataaag gcccctgggtg ttttaccaca 1320
gaccccagcg tcaggtggga gtactgcaac ctgaaaaaat gctcaggaac agaagcgagt 1380
gttgtagcac ctccgctgtg tgtcctgctt ccagatgtag agactccttc cgaagaagac 1440
tgtatgtttg ggaatgggaa aggataccga ggcaagaggg cgaccactgt tactgggacg 1500
ccatgccagg actgggctgc ccaggagccc catagacaca gcattttcac tccagagaca 1560
aatccacggg cgggtctgga aaaaaattac tgccgtaacc ctgatgggtga tgtaggtggg 1620
ccctgggtgct acacgacaaa tccaagaaaa ctttacgact actgtgatgt ccctcagtgt 1680
gcggccctt catttgattg tgggaagcct caagtggagc cgaagaaatg tcctggaagg 1740
gttgtggggg ggtgtgtggc ccaccacat tcctggccct ggcaagtcag tcttagaaca 1800

aggtttggaa tgcacttctg tggaggcacc ttgatatccc cagagtgggt gttgactgct 1860
 gcccactgct tggagaagtc cccaaggcct tcatactaca aggtcatcct ggggtgcacac 1920
 caagaagtga atctcgaacc gcatgttcag gaaatagaag tgtctaggct gttcttggag 1980
 cccacacgaa aagatattgc cttgctaaag ctaagcagtc ctgccgtcat cactgacaaa 2040
 gtaatcccag cttgtctgcc atccccaaat tatgtggctg ctgaccggac cgaatgtttc 2100
 atcactggct ggggagaaac ccaagggtact tttggagctg gccttctcaa ggaagcccag 2160
 ctccctgtga ttgagaataa agtgtgcaat cgctatgagt ttctgaatgg aagagtccaa 2220
 tccaccgaac tctgtgctgg gcatttggcc ggaggcactg acagttgcca ggggtgacagt 2280
 ggaggtcctc tggtttgctt cgagaaggac aaatacattt tacaaggagt cacttcttgg 2340
 ggtcttggct gtgcacgccc caataagcct ggtgtctatg ttcgtgtttc aaggtttggt 2400
 acttgattg agggagtgat gagaaataat 2430

<210> 4
 <211> 810
 <212> PRT
 <213> Homo sapiens

<400> 4

Met Glu His Lys Glu Val Val Leu Leu Leu Leu Phe Leu Lys Ser
1 5 10 15

Gly Gln Gly Glu Pro Leu Asp Asp Tyr Val Asn Thr Gln Gly Ala Ser
20 25 30

Leu Phe Ser Val Thr Lys Lys Gln Leu Gly Ala Gly Ser Ile Glu Glu
35 40 45

Cys Ala Ala Lys Cys Glu Glu Asp Glu Glu Phe Thr Cys Arg Ala Phe
50 55 60

Gln Tyr His Ser Lys Glu Gln Gln Cys Val Ile Met Ala Glu Asn Arg
65 70 75 80

Lys Ser Ser Ile Ile Ile Arg Met Arg Asp Val Val Leu Phe Glu Lys
85 90 95

Lys Val Tyr Leu Ser Glu Cys Lys Thr Gly Asn Gly Lys Asn Tyr Arg
100 105 110

Gly Thr Met Ser Lys Thr Lys Asn Gly Ile Thr Cys Gln Lys Trp Ser
115 120 125

Ser Thr Ser Pro His Arg Pro Arg Phe Ser Pro Ala Thr His Pro Ser
130 135 140

Glu Gly Leu Glu Glu Asn Tyr Cys Arg Asn Pro Asp Asn Asp Pro Gln
145 150 155 160

Gly Pro Trp Cys Tyr Thr Thr Asp Pro Glu Lys Arg Tyr Asp Tyr Cys
165 170 175

Asp Ile Leu Glu Cys Glu Glu Glu Cys Met His Cys Ser Gly Glu Asn

T126

	180	185	190
Tyr Asp Gly Lys Ile Ser Lys Thr Met Ser Gly Leu Glu Cys Gln Ala	195	200	205
Trp Asp Ser Gln Ser Pro His Ala His Gly Tyr Ile Pro Ser Lys Phe	210	215	220
Pro Asn Lys Asn Leu Lys Lys Asn Tyr Cys Arg Asn Pro Asp Arg Glu	225	230	240
Leu Arg Pro Trp Cys Phe Thr Thr Asp Pro Asn Lys Arg Trp Glu Leu	245	250	255
Cys Asp Ile Pro Arg Cys Thr Thr Pro Pro Pro Ser Ser Gly Pro Thr	260	265	270
Tyr Gln Cys Leu Lys Gly Thr Gly Glu Asn Tyr Arg Gly Asn Val Ala	275	280	285
Val Thr Val Ser Gly His Thr Cys Gln His Trp Ser Ala Gln Thr Pro	290	295	300
His Thr His Asn Arg Thr Pro Glu Asn Phe Pro Cys Lys Asn Leu Asp	305	310	320
Glu Asn Tyr Cys Arg Asn Pro Asp Gly Lys Arg Ala Pro Trp Cys His	325	330	335
Thr Thr Asn Ser Gln Val Arg Trp Glu Tyr Cys Lys Ile Pro Ser Cys	340	345	350
Asp Ser Ser Pro Val Ser Thr Glu Gln Leu Ala Pro Thr Ala Pro Pro	355	360	365
Glu Leu Thr Pro Val Val Gln Asp Cys Tyr His Gly Asp Gly Gln Ser	370	375	380
Tyr Arg Gly Thr Ser Ser Thr Thr Thr Thr Gly Lys Lys Cys Gln Ser	385	390	395
Trp Ser Ser Met Thr Pro His Arg His Gln Lys Thr Pro Glu Asn Tyr	405	410	415
Pro Asn Ala Gly Leu Thr Met Asn Tyr Cys Arg Asn Pro Asp Ala Asp	420	425	430
Lys Gly Pro Trp Cys Phe Thr Thr Asp Pro Ser Val Arg Trp Glu Tyr	435	440	445
Cys Asn Leu Lys Lys Cys Ser Gly Thr Glu Ala Ser Val Val Ala Pro	450	455	460
Pro Pro Val Val Leu Leu Pro Asp Val Glu Thr Pro Ser Glu Glu Asp	465	470	475
Cys Met Phe Gly Asn Gly Lys Gly Tyr Arg Gly Lys Arg Ala Thr Thr			

T126

485	490	495
Val Thr Gly Thr 500 Pro Cys Gln Asp Trp 505 Ala Ala Gln Glu Pro 510 His Arg		
His Ser Ile 515 Phe Thr Pro Glu Thr 520 Asn Pro Arg Ala Gly 525 Leu Glu Lys		
Asn Tyr 530 Cys Arg Asn Pro Asp 535 Gly Asp Val Gly Gly 540 Pro Trp Cys Tyr		
Thr 545 Thr Asn Pro Arg Lys 550 Leu Tyr Asp Tyr Cys 555 Asp Val Pro Gln Cys 560		
Ala Ala Pro Ser Phe 565 Asp Cys Gly Lys Pro 570 Gln Val Glu Pro Lys 575 Lys		
Cys Pro Gly Arg 580 Val Val Gly Gly Cys 585 Val Ala His Pro His 590 Ser Trp		
Pro Trp Gln 595 Val Ser Leu Arg Thr 600 Arg Phe Gly Met His 605 Phe Cys Gly		
Gly Thr 610 Leu Ile Ser Pro Glu 615 Trp Val Leu Thr Ala 620 Ala His Cys Leu		
Glu 625 Lys Ser Pro Arg Pro 630 Ser Ser Tyr Lys Val 635 Ile Leu Gly Ala His 640		
Gln Glu Val Asn 645 Leu Glu Pro His Val Gln 650 Glu Ile Glu Val Ser 655 Arg		
Leu Phe Leu 660 Glu Pro Thr Arg Lys Asp 665 Ile Ala Leu Leu Lys 670 Leu Ser		
Ser Pro Ala 675 Val Ile Thr Asp Lys 680 Val Ile Pro Ala Cys 685 Leu Pro Ser		
Pro Asn Tyr 690 Val Val Ala Asp 695 Arg Thr Glu Cys Phe 700 Ile Thr Gly Trp		
Gly 705 Glu Thr Gln Gly Thr 710 Phe Gly Ala Gly Leu 715 Leu Lys Glu Ala Gln 720		
Leu Pro Val Ile 725 Glu Asn Lys Val Cys 730 Arg Tyr Glu Phe Leu 735 Asn		
Gly Arg Val 740 Gln Ser Thr Glu Leu Cys 745 Ala Gly His Leu Ala 750 Gly Gly		
Thr Asp 755 Ser Cys Gln Gly Asp Ser 760 Gly Gly Pro Leu Val 765 Cys Phe Glu		
Lys Asp 770 Lys Tyr Ile Leu Gln 775 Gly Val Thr Ser Trp 780 Gly Leu Gly Cys		
Ala Arg Pro Asn Lys Pro Gly Val Tyr Val Arg Val Ser Arg Phe Val		

785 790 795 800
 T126
 Thr Trp Ile Glu Gly Val Met Arg Asn Asn
 805 810

 <210> 5
 <211> 791
 <212> PRT
 <213> Homo sapiens

 <400> 5
 Glu Pro Leu Asp Asp Tyr Val Asn Thr Gln Gly Ala Ser Leu Phe Ser
 1 5 10 15

 Val Thr Lys Lys Gln Leu Gly Ala Gly Ser Ile Glu Glu Cys Ala Ala
 20 25 30

 Lys Cys Glu Glu Asp Glu Glu Phe Thr Cys Arg Ala Phe Gln Tyr His
 35 40 45

 Ser Lys Glu Gln Gln Cys Val Ile Met Ala Glu Asn Arg Lys Ser Ser
 50 55 60

 Ile Ile Ile Arg Met Arg Asp Val Val Leu Phe Glu Lys Lys Val Tyr
 65 70 75 80

 Leu Ser Glu Cys Lys Thr Gly Asn Gly Lys Asn Tyr Arg Gly Thr Met
 85 90 95

 Ser Lys Thr Lys Asn Gly Ile Thr Cys Gln Lys Trp Ser Ser Thr Ser
 100 105 110

 Pro His Arg Pro Arg Phe Ser Pro Ala Thr His Pro Ser Glu Gly Leu
 115 120 125

 Glu Glu Asn Tyr Cys Arg Asn Pro Asp Asn Asp Pro Gln Gly Pro Trp
 130 135 140

 Cys Tyr Thr Thr Asp Pro Glu Lys Arg Tyr Asp Tyr Cys Asp Ile Leu
 145 150 155 160

 Glu Cys Glu Glu Glu Cys Met His Cys Ser Gly Glu Asn Tyr Asp Gly
 165 170 175

 Lys Ile Ser Lys Thr Met Ser Gly Leu Glu Cys Gln Ala Trp Asp Ser
 180 185 190

 Gln Ser Pro His Ala His Gly Tyr Ile Pro Ser Lys Phe Pro Asn Lys
 195 200 205

 Asn Leu Lys Lys Asn Tyr Cys Arg Asn Pro Asp Arg Glu Leu Arg Pro
 210 215 220

 Trp Cys Phe Thr Thr Asp Pro Asn Lys Arg Trp Glu Leu Cys Asp Ile
 225 230 235 240

 Pro Arg Cys Thr Thr Pro Pro Pro Ser Ser Gly Pro Thr Tyr Gln Cys
 245 250 255

Leu Lys Gly Thr Gly Glu Asn Tyr Arg Gly Asn Val Ala Val Thr Val
 260 265 270
 Ser Gly His Thr Cys Gln His Trp Ser Ala Gln Thr Pro His Thr His
 275 280 285
 Asn Arg Thr Pro Glu Asn Phe Pro Cys Lys Asn Leu Asp Glu Asn Tyr
 290 295 300
 Cys Arg Asn Pro Asp Gly Lys Arg Ala Pro Trp Cys His Thr Thr Asn
 305 310 315 320
 Ser Gln Val Arg Trp Glu Tyr Cys Lys Ile Pro Ser Cys Asp Ser Ser
 325 330 335
 Pro Val Ser Thr Glu Gln Leu Ala Pro Thr Ala Pro Pro Glu Leu Thr
 340 345 350
 Pro Val Val Gln Asp Cys Tyr His Gly Asp Gly Gln Ser Tyr Arg Gly
 355 360 365
 Thr Ser Ser Thr Thr Thr Thr Gly Lys Lys Cys Gln Ser Trp Ser Ser
 370 375 380
 Met Thr Pro His Arg His Gln Lys Thr Pro Glu Asn Tyr Pro Asn Ala
 385 390 395 400
 Gly Leu Thr Met Asn Tyr Cys Arg Asn Pro Asp Ala Asp Lys Gly Pro
 405 410 415
 Trp Cys Phe Thr Thr Asp Pro Ser Val Arg Trp Glu Tyr Cys Asn Leu
 420 425 430
 Lys Lys Cys Ser Gly Thr Glu Ala Ser Val Val Ala Pro Pro Pro Val
 435 440 445
 Val Leu Leu Pro Asp Val Glu Thr Pro Ser Glu Glu Asp Cys Met Phe
 450 455 460
 Gly Asn Gly Lys Gly Tyr Arg Gly Lys Arg Ala Thr Thr Val Thr Gly
 465 470 475 480
 Thr Pro Cys Gln Asp Trp Ala Ala Gln Glu Pro His Arg His Ser Ile
 485 490 495
 Phe Thr Pro Glu Thr Asn Pro Arg Ala Gly Leu Glu Lys Asn Tyr Cys
 500 505 510
 Arg Asn Pro Asp Gly Asp Val Gly Gly Pro Trp Cys Tyr Thr Thr Asn
 515 520 525
 Pro Arg Lys Leu Tyr Asp Tyr Cys Asp Val Pro Gln Cys Ala Ala Pro
 530 535 540
 Ser Phe Asp Cys Gly Lys Pro Gln Val Glu Pro Lys Lys Cys Pro Gly
 545 550 555 560

Arg Val Val Gly Gly Cys Val Ala His Pro His Ser Trp Pro Trp Gln
 565 570 575
 Val Ser Leu Arg Thr Arg Phe Gly Met His Phe Cys Gly Gly Thr Leu
 580 585 590
 Ile Ser Pro Glu Trp Val Leu Thr Ala Ala His Cys Leu Glu Lys Ser
 595 600 605
 Pro Arg Pro Ser Ser Tyr Lys Val Ile Leu Gly Ala His Gln Glu Val
 610 615 620
 Asn Leu Glu Pro His Val Gln Glu Ile Glu Val Ser Arg Leu Phe Leu
 625 630 635 640
 Glu Pro Thr Arg Lys Asp Ile Ala Leu Leu Lys Leu Ser Ser Pro Ala
 645 650 655
 Val Ile Thr Asp Lys Val Ile Pro Ala Cys Leu Pro Ser Pro Asn Tyr
 660 665 670
 Val Val Ala Asp Arg Thr Glu Cys Phe Ile Thr Gly Trp Gly Glu Thr
 675 680 685
 Gln Gly Thr Phe Gly Ala Gly Leu Leu Lys Glu Ala Gln Leu Pro Val
 690 695 700
 Ile Glu Asn Lys Val Cys Asn Arg Tyr Glu Phe Leu Asn Gly Arg Val
 705 710 715 720
 Gln Ser Thr Glu Leu Cys Ala Gly His Leu Ala Gly Gly Thr Asp Ser
 725 730 735
 Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Cys Phe Glu Lys Asp Lys
 740 745 750
 Tyr Ile Leu Gln Gly Val Thr Ser Trp Gly Leu Gly Cys Ala Arg Pro
 755 760 765
 Asn Lys Pro Gly Val Tyr Val Arg Val Ser Arg Phe Val Thr Trp Ile
 770 775 780
 Glu Gly Val Met Arg Asn Asn
 785 790
 <210> 6
 <211> 723
 <212> PRT
 <213> Homo sapiens
 <400> 6
 Met Arg Asp Val Val Leu Phe Glu Lys Lys Val Tyr Leu Ser Glu Cys
 1 5 10 15
 Lys Thr Gly Asn Gly Lys Asn Tyr Arg Gly Thr Met Ser Lys Thr Lys
 20 25 30

Asn Gly Ile Thr Cys Gln Lys Trp Ser Ser Thr Ser Pro His Arg Pro
 35 40 45
 Arg Phe Ser Pro Ala Thr His Pro Ser Glu Gly Leu Glu Glu Asn Tyr
 50 55 60
 Cys Arg Asn Pro Asp Asn Asp Pro Gln Gly Pro Trp Cys Tyr Thr Thr
 65 70 75 80
 Asp Pro Glu Lys Arg Tyr Asp Tyr Cys Asp Ile Leu Glu Cys Glu Glu
 85 90 95
 Glu Cys Met His Cys Ser Gly Glu Asn Tyr Asp Gly Lys Ile Ser Lys
 100 105 110
 Thr Met Ser Gly Leu Glu Cys Gln Ala Trp Asp Ser Gln Ser Pro His
 115 120 125
 Ala His Gly Tyr Ile Pro Ser Lys Phe Pro Asn Lys Asn Leu Lys Lys
 130 135 140
 Asn Tyr Cys Arg Asn Pro Asp Arg Glu Leu Arg Pro Trp Cys Phe Thr
 145 150 155 160
 Thr Asp Pro Asn Lys Arg Trp Glu Leu Cys Asp Ile Pro Arg Cys Thr
 165 170 175
 Thr Pro Pro Pro Ser Ser Gly Pro Thr Tyr Gln Cys Leu Lys Gly Thr
 180 185 190
 Gly Glu Asn Tyr Arg Gly Asn Val Ala Val Thr Val Ser Gly His Thr
 195 200 205
 Cys Gln His Trp Ser Ala Gln Thr Pro His Thr His Asn Arg Thr Pro
 210 215 220
 Glu Asn Phe Pro Cys Lys Asn Leu Asp Glu Asn Tyr Cys Arg Asn Pro
 225 230 235 240
 Asp Gly Lys Arg Ala Pro Trp Cys His Thr Thr Asn Ser Gln Val Arg
 245 250 255
 Trp Glu Tyr Cys Lys Ile Pro Ser Cys Asp Ser Ser Pro Val Ser Thr
 260 265 270
 Glu Gln Leu Ala Pro Thr Ala Pro Pro Glu Leu Thr Pro Val Val Gln
 275 280 285
 Asp Cys Tyr His Gly Asp Gly Gln Ser Tyr Arg Gly Thr Ser Ser Thr
 290 295 300
 Thr Thr Thr Gly Lys Lys Cys Gln Ser Trp Ser Ser Met Thr Pro His
 305 310 315 320
 Arg His Gln Lys Thr Pro Glu Asn Tyr Pro Asn Ala Gly Leu Thr Met
 325 330 335

Asn Tyr Cys Arg Asn Pro Asp Ala Asp Lys Gly Pro Trp Cys Phe Thr
 340 345 350
 Thr Asp Pro Ser Val Arg Trp Glu Tyr Cys Asn Leu Lys Lys Cys Ser
 355 360 365
 Gly Thr Glu Ala Ser Val Val Ala Pro Pro Pro Val Val Leu Leu Pro
 370 375 380
 Asp Val Glu Thr Pro Ser Glu Glu Asp Cys Met Phe Gly Asn Gly Lys
 385 390 395 400
 Gly Tyr Arg Gly Lys Arg Ala Thr Thr Val Thr Gly Thr Pro Cys Gln
 405 410 415
 Asp Trp Ala Ala Gln Glu Pro His Arg His Ser Ile Phe Thr Pro Glu
 420 425 430
 Thr Asn Pro Arg Ala Gly Leu Glu Lys Asn Tyr Cys Arg Asn Pro Asp
 435 440 445
 Gly Asp Val Gly Gly Pro Trp Cys Tyr Thr Thr Asn Pro Arg Lys Leu
 450 455 460
 Tyr Asp Tyr Cys Asp Val Pro Gln Cys Ala Ala Pro Ser Phe Asp Cys
 465 470 475 480
 Gly Lys Pro Gln Val Glu Pro Lys Lys Cys Pro Gly Arg Val Val Gly
 485 490 495
 Gly Cys Val Ala His Pro His Ser Trp Pro Trp Gln Val Ser Leu Arg
 500 505 510
 Thr Arg Phe Gly Met His Phe Cys Gly Gly Thr Leu Ile Ser Pro Glu
 515 520 525
 Trp Val Leu Thr Ala Ala His Cys Leu Glu Lys Ser Pro Arg Pro Ser
 530 535 540
 Ser Tyr Lys Val Ile Leu Gly Ala His Gln Glu Val Asn Leu Glu Pro
 545 550 555 560
 His Val Gln Glu Ile Glu Val Ser Arg Leu Phe Leu Glu Pro Thr Arg
 565 570 575
 Lys Asp Ile Ala Leu Leu Lys Leu Ser Ser Pro Ala Val Ile Thr Asp
 580 585 590
 Lys Val Ile Pro Ala Cys Leu Pro Ser Pro Asn Tyr Val Val Ala Asp
 595 600 605
 Arg Thr Glu Cys Phe Ile Thr Gly Trp Gly Glu Thr Gln Gly Thr Phe
 610 615 620
 Gly Ala Gly Leu Leu Lys Glu Ala Gln Leu Pro Val Ile Glu Asn Lys
 625 630 635 640

Val Cys Asn Arg Tyr Glu Phe Leu Asn Gly Arg Val Gln Ser Thr Glu
645 650 655

Leu Cys Ala Gly His Leu Ala Gly Gly Thr Asp Ser Cys Gln Gly Asp
660 665 670

Ser Gly Gly Pro Leu Val Cys Phe Glu Lys Asp Lys Tyr Ile Leu Gln
675 680 685

Gly Val Thr Ser Trp Gly Leu Gly Cys Ala Arg Pro Asn Lys Pro Gly
690 695 700

Val Tyr Val Arg Val Ser Arg Phe Val Thr Trp Ile Glu Gly Val Met
705 710 715 720

Arg Asn Asn

<210> 7
<211> 714
<212> PRT
<213> Homo sapiens

<400> 7

Lys Val Tyr Leu Ser Glu Cys Lys Thr Gly Asn Gly Lys Asn Tyr Arg
1 5 10 15

Gly Thr Met Ser Lys Thr Lys Asn Gly Ile Thr Cys Gln Lys Trp Ser
20 25 30

Ser Thr Ser Pro His Arg Pro Arg Phe Ser Pro Ala Thr His Pro Ser
35 40 45

Glu Gly Leu Glu Glu Asn Tyr Cys Arg Asn Pro Asp Asn Asp Pro Gln
50 55 60

Gly Pro Trp Cys Tyr Thr Thr Asp Pro Glu Lys Arg Tyr Asp Tyr Cys
65 70 75 80

Asp Ile Leu Glu Cys Glu Glu Glu Cys Met His Cys Ser Gly Glu Asn
85 90 95

Tyr Asp Gly Lys Ile Ser Lys Thr Met Ser Gly Leu Glu Cys Gln Ala
100 105 110

Trp Asp Ser Gln Ser Pro His Ala His Gly Tyr Ile Pro Ser Lys Phe
115 120 125

Pro Asn Lys Asn Leu Lys Lys Asn Tyr Cys Arg Asn Pro Asp Arg Glu
130 135 140

Leu Arg Pro Trp Cys Phe Thr Thr Asp Pro Asn Lys Arg Trp Glu Leu
145 150 155 160

Cys Asp Ile Pro Arg Cys Thr Thr Pro Pro Ser Ser Gly Pro Thr
165 170 175

Tyr Gln Cys Leu Lys Gly Thr Gly Glu Asn Tyr Arg Gly Asn Val Ala
 180 185 T126
 Val Thr Val Ser Gly His Thr Cys Gln His Trp Ser Ala Gln Thr Pro
 195 200 205
 His Thr His Asn Arg Thr Pro Glu Asn Phe Pro Cys Lys Asn Leu Asp
 210 215 220
 Glu Asn Tyr Cys Arg Asn Pro Asp Gly Lys Arg Ala Pro Trp Cys His
 225 230 235 240
 Thr Thr Asn Ser Gln Val Arg Trp Glu Tyr Cys Lys Ile Pro Ser Cys
 245 250 255
 Asp Ser Ser Pro Val Ser Thr Glu Gln Leu Ala Pro Thr Ala Pro Pro
 260 265 270
 Glu Leu Thr Pro Val Val Gln Asp Cys Tyr His Gly Asp Gly Gln Ser
 275 280 285
 Tyr Arg Gly Thr Ser Ser Thr Thr Thr Thr Gly Lys Lys Cys Gln Ser
 290 295 300
 Trp Ser Ser Met Thr Pro His Arg His Gln Lys Thr Pro Glu Asn Tyr
 305 310 315 320
 Pro Asn Ala Gly Leu Thr Met Asn Tyr Cys Arg Asn Pro Asp Ala Asp
 325 330 335
 Lys Gly Pro Trp Cys Phe Thr Thr Asp Pro Ser Val Arg Trp Glu Tyr
 340 345 350
 Cys Asn Leu Lys Lys Cys Ser Gly Thr Glu Ala Ser Val Val Ala Pro
 355 360 365
 Pro Pro Val Val Leu Leu Pro Asp Val Glu Thr Pro Ser Glu Glu Asp
 370 375 380
 Cys Met Phe Gly Asn Gly Lys Gly Tyr Arg Gly Lys Arg Ala Thr Thr
 385 390 395 400
 Val Thr Gly Thr Pro Cys Gln Asp Trp Ala Ala Gln Glu Pro His Arg
 405 410 415
 His Ser Ile Phe Thr Pro Glu Thr Asn Pro Arg Ala Gly Leu Glu Lys
 420 425 430
 Asn Tyr Cys Arg Asn Pro Asp Gly Asp Val Gly Gly Pro Trp Cys Tyr
 435 440 445
 Thr Thr Asn Pro Arg Lys Leu Tyr Asp Tyr Cys Asp Val Pro Gln Cys
 450 455 460
 Ala Ala Pro Ser Phe Asp Cys Gly Lys Pro Gln Val Glu Pro Lys Lys
 465 470 475 480

T126

Cys Pro Gly Arg Val Val Gly Gly Cys Val Ala His Pro His Ser Trp
485 490 495

Pro Trp Gln Val Ser Leu Arg Thr Arg Phe Gly Met His Phe Cys Gly
500 505 510

Gly Thr Leu Ile Ser Pro Glu Trp Val Leu Thr Ala Ala His Cys Leu
515 520 525

Glu Lys Ser Pro Arg Pro Ser Ser Tyr Lys Val Ile Leu Gly Ala His
530 535 540

Gln Glu Val Asn Leu Glu Pro His Val Gln Glu Ile Glu Val Ser Arg
545 550 555 560

Leu Phe Leu Glu Pro Thr Arg Lys Asp Ile Ala Leu Leu Lys Leu Ser
565 570 575

Ser Pro Ala Val Ile Thr Asp Lys Val Ile Pro Ala Cys Leu Pro Ser
580 585 590

Pro Asn Tyr Val Val Ala Asp Arg Thr Glu Cys Phe Ile Thr Gly Trp
595 600 605

Gly Glu Thr Gln Gly Thr Phe Gly Ala Gly Leu Leu Lys Glu Ala Gln
610 615 620

Leu Pro Val Ile Glu Asn Lys Val Cys Asn Arg Tyr Glu Phe Leu Asn
625 630 635 640

Gly Arg Val Gln Ser Thr Glu Leu Cys Ala Gly His Leu Ala Gly Gly
645 650 655

Thr Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Cys Phe Glu
660 665 670

Lys Asp Lys Tyr Ile Leu Gln Gly Val Thr Ser Trp Gly Leu Gly Cys
675 680 685

Ala Arg Pro Asn Lys Pro Gly Val Tyr Val Arg Val Ser Arg Phe Val
690 695 700

Thr Trp Ile Glu Gly Val Met Arg Asn Asn
705 710

<210> 8
<211> 713
<212> PRT
<213> Homo sapiens

<400> 8

Val Tyr Leu Ser Glu Cys Lys Thr Gly Asn Gly Lys Asn Tyr Arg Gly
1 5 10 15

Thr Met Ser Lys Thr Lys Asn Gly Ile Thr Cys Gln Lys Trp Ser Ser
20 25 30

Thr Ser Pro His Arg Pro Arg Phe Ser Pro Ala Thr His Pro Ser Glu

35

40

T126

45

Gly Leu Glu Glu Asn Tyr Cys Arg Asn Pro Asp Asn Asp Pro Gln Gly
 50 55 60

Pro Trp Cys Tyr Thr Thr Asp Pro Glu Lys Arg Tyr Asp Tyr Cys Asp
 65 70 75 80

Ile Leu Glu Cys Glu Glu Glu Cys Met His Cys Ser Gly Glu Asn Tyr
 85 90 95

Asp Gly Lys Ile Ser Lys Thr Met Ser Gly Leu Glu Cys Gln Ala Trp
 100 105 110

Asp Ser Gln Ser Pro His Ala His Gly Tyr Ile Pro Ser Lys Phe Pro
 115 120 125

Asn Lys Asn Leu Lys Lys Asn Tyr Cys Arg Asn Pro Asp Arg Glu Leu
 130 135 140

Arg Pro Trp Cys Phe Thr Thr Asp Pro Asn Lys Arg Trp Glu Leu Cys
 145 150 155 160

Asp Ile Pro Arg Cys Thr Thr Pro Pro Pro Ser Ser Gly Pro Thr Tyr
 165 170 175

Gln Cys Leu Lys Gly Thr Gly Glu Asn Tyr Arg Gly Asn Val Ala Val
 180 185 190

Thr Val Ser Gly His Thr Cys Gln His Trp Ser Ala Gln Thr Pro His
 195 200 205

Thr His Asn Arg Thr Pro Glu Asn Phe Pro Cys Lys Asn Leu Asp Glu
 210 215 220

Asn Tyr Cys Arg Asn Pro Asp Gly Lys Arg Ala Pro Trp Cys His Thr
 225 230 235 240

Thr Asn Ser Gln Val Arg Trp Glu Tyr Cys Lys Ile Pro Ser Cys Asp
 245 250 255

Ser Ser Pro Val Ser Thr Glu Gln Leu Ala Pro Thr Ala Pro Pro Glu
 260 265 270

Leu Thr Pro Val Val Gln Asp Cys Tyr His Gly Asp Gly Gln Ser Tyr
 275 280 285

Arg Gly Thr Ser Ser Thr Thr Thr Thr Gly Lys Lys Cys Gln Ser Trp
 290 295 300

Ser Ser Met Thr Pro His Arg His Gln Lys Thr Pro Glu Asn Tyr Pro
 305 310 315 320

Asn Ala Gly Leu Thr Met Asn Tyr Cys Arg Asn Pro Asp Ala Asp Lys
 325 330 335

Gly Pro Trp Cys Phe Thr Thr Asp Pro Ser Val Arg Trp Glu Tyr Cys

T126

340	345	350	
Asn Leu Lys 355	Lys Cys Ser Gly Thr 360	Glu Ala Ser Val 365	Val Ala Pro Pro
Pro Val 370	Val Leu Leu Pro Asp 375	Val Glu Thr Pro Ser 380	Glu Glu Asp Cys
Met 385	Phe Gly Asn Gly Lys 390	Gly Tyr Arg Gly Lys 395	Arg Ala Thr Thr Val 400
Thr Gly Thr	Pro Cys 405	Gln Asp Trp Ala 410	Gln Glu Pro His Arg 415
Ser Ile Phe	Thr 420	Pro Glu Thr Asn Pro 425	Arg Ala Gly Leu Glu Lys Asn 430
Tyr Cys Arg 435	Asn Pro Asp Gly Asp 440	Val Gly Gly Pro Trp 445	Cys Tyr Thr
Thr Asn 450	Pro Arg Lys Leu Tyr 455	Asp Tyr Cys Asp Val 460	Pro Gln Cys Ala
Ala 465	Pro Ser Phe Asp Cys 470	Gly Lys Pro Gln Val 475	Glu Pro Lys Lys Cys 480
Pro Gly Arg Val 485	Val Gly Gly Cys Val 490	Ala His Pro His Ser Trp 495	Pro
Trp Gln Val 500	Ser Leu Arg Thr Arg Phe 505	Gly Met His Phe Cys 510	Gly Gly
Thr Leu Ile 515	Ser Pro Glu Trp Val 520	Leu Thr Ala Ala His 525	Cys Leu Glu
Lys Ser 530	Pro Arg Pro Ser Ser 535	Tyr Lys Val Ile Leu 540	Gly Ala His Gln
Glu Val 545	Asn Leu Glu Pro 550	His Val Gln Glu Ile 555	Glu Val Ser Arg Leu 560
Phe Leu Glu	Pro Thr 565	Arg Lys Asp Ile Ala 570	Leu Leu Lys Leu Ser 575
Pro Ala Val 580	Ile Thr Asp Lys Val 585	Ile Pro Ala Cys Leu 590	Pro Ser Pro
Asn Tyr Val 595	Val Ala Asp Arg Thr 600	Glu Cys Phe Ile Thr 605	Gly Trp Gly
Glu Thr 610	Gln Gly Thr Phe Gly 615	Ala Gly Leu Leu Lys 620	Glu Ala Gln Leu
Pro Val 625	Ile Glu Asn Lys 630	Val Cys Asn Arg Tyr 635	Glu Phe Leu Asn Gly 640
Arg Val Gln	Ser Thr Glu Leu Cys Ala Gly	His Leu Ala Gly Gly Thr	

645

650

655

Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Cys Phe Glu Lys
 660 665 670

Asp Lys Tyr Ile Leu Gln Gly Val Thr Ser Trp Gly Leu Gly Cys Ala
 675 680 685

Arg Pro Asn Lys Pro Gly Val Tyr Val Arg Val Ser Arg Phe Val Thr
 690 695 700

Trp Ile Glu Gly Val Met Arg Asn Asn
 705 710

<210> 9

<211> 335

<212> PRT

<213> Artificial Sequence

<220>

<223> Polypeptide having a single N-terminal kringle domain homologous
 to a kringle domain of a native human plasminogen

<400> 9

Lys Val Tyr Leu Ser Glu Cys Lys Thr Gly Asn Gly Lys Asn Tyr Arg
 1 5 10 15

Gly Thr Met Ser Lys Thr Lys Asn Gly Ile Thr Cys Gln Lys Trp Ser
 20 25 30

Ser Thr Ser Pro His Arg Pro Arg Phe Ser Pro Ala Thr His Pro Ser
 35 40 45

Glu Gly Leu Glu Glu Asn Tyr Cys Arg Asn Pro Asp Asn Asp Pro Gln
 50 55 60

Gly Pro Trp Cys Tyr Thr Thr Asp Pro Glu Lys Arg Tyr Asp Tyr Cys
 65 70 75 80

Asp Val Pro Gln Cys Ala Ala Pro Ser Phe Asp Cys Gly Lys Pro Gln
 85 90 95

Val Glu Pro Lys Lys Cys Pro Gly Arg Val Val Gly Gly Cys Val Ala
 100 105 110

His Pro His Ser Trp Pro Trp Gln Val Ser Leu Arg Thr Arg Phe Gly
 115 120 125

Met His Phe Cys Gly Gly Thr Leu Ile Ser Pro Glu Trp Val Leu Thr
 130 135 140

Ala Ala His Cys Leu Glu Lys Ser Pro Arg Pro Ser Ser Tyr Lys Val
 145 150 155 160

Ile Leu Gly Ala His Gln Glu Val Asn Leu Glu Pro His Val Gln Glu
 165 170 175

Ile Glu Val Ser Arg Leu Phe Leu Glu Pro Thr Arg Lys Asp Ile Ala
 180 185 190

Leu Leu Lys Leu Ser Ser Pro Ala Val Ile Thr Asp Lys Val Ile Pro
 195 200 205
 Ala Cys Leu Pro Ser Pro Asn Tyr Val Val Ala Asp Arg Thr Glu Cys
 210 215 220
 Phe Ile Thr Gly Trp Gly Glu Thr Gln Gly Thr Phe Gly Ala Gly Leu
 225 230 235 240
 Leu Lys Glu Ala Gln Leu Pro Val Ile Glu Asn Lys Val Cys Asn Arg
 245 250 255
 Tyr Glu Phe Leu Asn Gly Arg Val Gln Ser Thr Glu Leu Cys Ala Gly
 260 265 270
 His Leu Ala Gly Gly Thr Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro
 275 280 285
 Leu Val Cys Phe Glu Lys Asp Lys Tyr Ile Leu Gln Gly Val Thr Ser
 290 295 300
 Trp Gly Leu Gly Cys Ala Arg Pro Asn Lys Pro Gly Val Tyr Val Arg
 305 310 315 320
 Val Ser Arg Phe Val Thr Trp Ile Glu Gly Val Met Arg Asn Asn
 325 330 335
 <210> 10
 <211> 334
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> Polypeptide having a single N-terminal kringle domain homologous
 to a kringle domain of a native human plasminogen
 <400> 10
 Val Tyr Leu Ser Glu Cys Lys Thr Gly Asn Gly Lys Asn Tyr Arg Gly
 1 5 10 15
 Thr Met Ser Lys Thr Lys Asn Gly Ile Thr Cys Gln Lys Trp Ser Ser
 20 25 30
 Thr Ser Pro His Arg Pro Arg Phe Ser Pro Ala Thr His Pro Ser Glu
 35 40 45
 Gly Leu Glu Glu Asn Tyr Cys Arg Asn Pro Asp Asn Asp Pro Gln Gly
 50 55 60
 Pro Trp Cys Tyr Thr Thr Asp Pro Glu Lys Arg Tyr Asp Tyr Cys Asp
 65 70 75 80
 Val Pro Gln Cys Ala Ala Pro Ser Phe Asp Cys Gly Lys Pro Gln Val
 85 90 95
 Glu Pro Lys Lys Cys Pro Gly Arg Val Val Gly Gly Cys Val Ala His
 100 105 110

Pro His Ser Trp Pro Trp Gln Val Ser Leu Arg Thr Arg Phe Gly Met
 115 120 125

His Phe Cys Gly Gly Thr Leu Ile Ser Pro Glu Trp Val Leu Thr Ala
 130 135 140

Ala His Cys Leu Glu Lys Ser Pro Arg Pro Ser Ser Tyr Lys Val Ile
 145 150 155 160

Leu Gly Ala His Gln Glu Val Asn Leu Glu Pro His Val Gln Glu Ile
 165 170 175

Glu Val Ser Arg Leu Phe Leu Glu Pro Thr Arg Lys Asp Ile Ala Leu
 180 185 190

Leu Lys Leu Ser Ser Pro Ala Val Ile Thr Asp Lys Val Ile Pro Ala
 195 200 205

Cys Leu Pro Ser Pro Asn Tyr Val Val Ala Asp Arg Thr Glu Cys Phe
 210 215 220

Ile Thr Gly Trp Gly Glu Thr Gln Gly Thr Phe Gly Ala Gly Leu Leu
 225 230 235 240

Lys Glu Ala Gln Leu Pro Val Ile Glu Asn Lys Val Cys Asn Arg Tyr
 245 250 255

Glu Phe Leu Asn Gly Arg Val Gln Ser Thr Glu Leu Cys Ala Gly His
 260 265 270

Leu Ala Gly Gly Thr Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu
 275 280 285

Val Cys Phe Glu Lys Asp Lys Tyr Ile Leu Gln Gly Val Thr Ser Trp
 290 295 300

Gly Leu Gly Cys Ala Arg Pro Asn Lys Pro Gly Val Tyr Val Arg Val
 305 310 315 320

Ser Arg Phe Val Thr Trp Ile Glu Gly Val Met Arg Asn Asn
 325 330

<210> 11
 <211> 79
 <212> PRT
 <213> Homo sapiens

<220>
 <221> kringle1
 <222> (1)..(79)

<400> 11

Cys Lys Thr Gly Asn Gly Lys Asn Tyr Arg Gly Thr Met Ser Lys Thr
 1 5 10 15

Lys Asn Gly Ile Thr Cys Gln Lys Trp Ser Ser Thr Ser Pro His Arg
 20 25 30

Pro Arg Phe Ser Pro Ala Thr His Pro Ser Glu Gly Leu Glu Glu Asn
 35 40 45

Tyr Cys Arg Asn Pro Asp Asn Asp Pro Gln Gly Pro Trp Cys Tyr Thr
 50 55 60

Thr Asp Pro Glu Lys Arg Tyr Asp Tyr Cys Asp Ile Leu Glu Cys
 65 70 75

<210> 12
 <211> 78
 <212> PRT
 <213> Homo sapiens

<220>
 <221> kringle2
 <222> (1)..(78)

<400> 12

Cys Met His Cys Ser Gly Glu Asn Tyr Asp Gly Lys Ile Ser Lys Thr
 1 5 10 15

Met Ser Gly Leu Glu Cys Gln Ala Trp Asp Ser Gln Ser Pro His Ala
 20 25 30

His Gly Tyr Ile Pro Ser Lys Phe Pro Asn Lys Asn Leu Lys Lys Asn
 35 40 45

Tyr Cys Arg Asn Pro Asp Arg Glu Leu Arg Pro Trp Cys Phe Thr Thr
 50 55 60

Asp Pro Asn Lys Arg Trp Glu Leu Cys Asp Ile Pro Arg Cys
 65 70 75

<210> 13
 <211> 78
 <212> PRT
 <213> Homo sapiens

<220>
 <221> kringle3
 <222> (1)..(78)

<400> 13

Cys Leu Lys Gly Thr Gly Glu Asn Tyr Arg Gly Asn Val Ala Val Thr
 1 5 10 15

Val Ser Gly His Thr Cys Gln His Trp Ser Ala Gln Thr Pro His Thr
 20 25 30

His Asn Arg Thr Pro Glu Asn Phe Pro Cys Lys Asn Leu Asp Glu Asn
 35 40 45

Tyr Cys Arg Asn Pro Asp Gly Lys Arg Ala Pro Trp Cys His Thr Thr
 50 55 60

Asn Ser Gln Val Arg Trp Glu Tyr Cys Lys Ile Pro Ser Cys
 65 70 75

<210> 14
 <211> 78
 <212> PRT
 <213> Homo sapiens

<220>
 <221> kringle4
 <222> (1)..(78)

<400> 14

Cys Tyr His Gly Asp Gly Gln Ser Tyr Arg Gly Thr Ser Ser Thr Thr
 1 5 10 15

Thr Thr Gly Lys Lys Cys Gln Ser Trp Ser Ser Met Thr Pro His Arg
 20 25 30

His Gln Lys Thr Pro Glu Asn Tyr Pro Asn Ala Gly Leu Thr Met Asn
 35 40 45

Tyr Cys Arg Asn Pro Asp Ala Asp Lys Gly Pro Trp Cys Phe Thr Thr
 50 55 60

Asp Pro Ser Val Arg Trp Glu Tyr Cys Asn Leu Lys Lys Cys
 65 70 75

<210> 15
 <211> 80
 <212> PRT
 <213> Homo sapiens

<220>
 <221> kringle5
 <222> (1)..(80)

<400> 15

Cys Met Phe Gly Asn Gly Lys Gly Tyr Arg Gly Lys Arg Ala Thr Thr
 1 5 10 15

Val Thr Gly Thr Pro Cys Gln Asp Trp Ala Ala Gln Glu Pro His Arg
 20 25 30

His Ser Ile Phe Thr Pro Glu Thr Asn Pro Arg Ala Gly Leu Glu Lys
 35 40 45

Asn Tyr Cys Arg Asn Pro Asp Gly Asp Val Gly Gly Pro Trp Cys Tyr
 50 55 60

Thr Thr Asn Pro Arg Lys Leu Tyr Asp Tyr Cys Asp Val Pro Gln Cys
 65 70 75 80